<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39370939</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1398-9995</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>07</Day></PubDate></JournalIssue><Title>Allergy</Title><ISOAbbreviation>Allergy</ISOAbbreviation></Journal><ArticleTitle>The epithelial barrier theory and its associated diseases.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1111/all.16318</ELocationID><Abstract><AbstractText>The prevalence of many chronic noncommunicable diseases has been steadily rising over the past six decades. During this time, over 350,000 new chemical substances have been introduced to the lives of humans. In recent years, the epithelial barrier theory came to light explaining the growing prevalence and exacerbations of these diseases worldwide. It attributes their onset to a functionally impaired epithelial barrier triggered by the toxicity of the exposed substances, associated with microbial dysbiosis, immune system activation, and inflammation. Diseases encompassed by the epithelial barrier theory share common features such as an increased prevalence after the 1960s or 2000s that cannot (solely) be accounted for by the emergence of improved diagnostic methods. Other common traits include epithelial barrier defects, microbial dysbiosis with loss of commensals and colonization of opportunistic pathogens, and circulating inflammatory cells and cytokines. In addition, practically unrelated diseases that fulfill these criteria have started to emerge as multimorbidities during the last decades. Here, we provide a comprehensive overview of diseases encompassed by the epithelial barrier theory and discuss evidence and similarities for their epidemiology, genetic susceptibility, epithelial barrier dysfunction, microbial dysbiosis, and tissue inflammation.</AbstractText><CopyrightInformation>© 2024 The Author(s). Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Na</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-9936-6907</Identifier><AffiliationInfo><Affiliation>Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>SKL of Marine Food Processing &amp; Safety Control, National Engineering Research Center of Seafood, School of Food Science and Technology, Dalian Polytechnic University, Dalian, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ogulur</LastName><ForeName>Ismail</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0001-8282-7762</Identifier><AffiliationInfo><Affiliation>Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mitamura</LastName><ForeName>Yasutaka</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0001-6389-9285</Identifier><AffiliationInfo><Affiliation>Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yazici</LastName><ForeName>Duygu</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-9094-6542</Identifier><AffiliationInfo><Affiliation>Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pat</LastName><ForeName>Yagiz</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0003-4268-4933</Identifier><AffiliationInfo><Affiliation>Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bu</LastName><ForeName>Xiangting</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Manru</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Xueyi</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Babayev</LastName><ForeName>Huseyn</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-6985-9436</Identifier><AffiliationInfo><Affiliation>Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ardicli</LastName><ForeName>Sena</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-2758-5945</Identifier><AffiliationInfo><Affiliation>Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics, Faculty of Veterinary Medicine, Bursa Uludag University, Bursa, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ardicli</LastName><ForeName>Ozge</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0001-6077-0478</Identifier><AffiliationInfo><Affiliation>Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Food Processing, Milk and Dairy Products Technology Program, Karacabey Vocational School, Bursa Uludag University, Bursa, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Avino</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kiykim</LastName><ForeName>Ayca</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-5821-3963</Identifier><AffiliationInfo><Affiliation>Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Division of Pediatric Allergy and Immunology, Cerrahpasa School of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sokolowska</LastName><ForeName>Milena</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-9710-6685</Identifier><AffiliationInfo><Affiliation>Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van de Veen</LastName><ForeName>Willem</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weidmann</LastName><ForeName>Lukas</ForeName><Initials>L</Initials><Identifier Source="ORCID">0009-0001-4948-0995</Identifier><AffiliationInfo><Affiliation>Department of Nephrology, University Hospital Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akdis</LastName><ForeName>Deniz</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-4561-3540</Identifier><AffiliationInfo><Affiliation>Department of Cardiology, University Hospital Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ozdemir</LastName><ForeName>Banu Goker</ForeName><Initials>BG</Initials><Identifier Source="ORCID">0009-0005-5220-0869</Identifier><AffiliationInfo><Affiliation>Obstetrician and Gynecologist, Nisantasi, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brüggen</LastName><ForeName>Marie Charlotte</ForeName><Initials>MC</Initials><Identifier Source="ORCID">0000-0002-8607-6254</Identifier><AffiliationInfo><Affiliation>Christine Kühne-Center for Allergy Research and Education (CK-CARE), Davos, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, University of Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Biedermann</LastName><ForeName>Luc</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-0824-4125</Identifier><AffiliationInfo><Affiliation>Department of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Straumann</LastName><ForeName>Alex</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kreienbühl</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guttman-Yassky</LastName><ForeName>Emma</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-9363-324X</Identifier><AffiliationInfo><Affiliation>Department of Dermatology, and Laboratory of Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santos</LastName><ForeName>Alexandra F</ForeName><Initials>AF</Initials><Identifier Source="ORCID">0000-0002-7805-1436</Identifier><AffiliationInfo><Affiliation>Department of Women and Children's Health (Pediatric Allergy), School of Life Course Sciences, Faculty of Life Sciences and Medicine, King's College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Children's Allergy Service, Evelina London Children's Hospital, Guy's and St. Thomas' Hospital, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Del Giacco</LastName><ForeName>Stefano</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-4517-1749</Identifier><AffiliationInfo><Affiliation>Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Traidl-Hoffmann</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-5085-5179</Identifier><AffiliationInfo><Affiliation>Environmental Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jackson</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><Identifier Source="ORCID">0000-0002-2299-868X</Identifier><AffiliationInfo><Affiliation>Guy's Severe Asthma Centre, Guy's Hospital, Guy's &amp; St Thomas' NHS Trust, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Immunology &amp; Microbial Sciences, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>De-Yun</ForeName><Initials>DY</Initials><Identifier Source="ORCID">0000-0002-0909-2963</Identifier><AffiliationInfo><Affiliation>Department of Otolaryngology, Infectious Diseases Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, National University Health System, Singapore City, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lauerma</LastName><ForeName>Antti</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-5078-3547</Identifier><AffiliationInfo><Affiliation>Department of Dermatology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Breiteneder</LastName><ForeName>Heimo</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-2022-8689</Identifier><AffiliationInfo><Affiliation>Department of Pathophysiology and Allergy Research, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Luo</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-0910-9884</Identifier><AffiliationInfo><Affiliation>Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Beijing Laboratory of Allergic Diseases and Beijing Key Laboratory of Nasal Diseases, Beijing Institute of Otolaryngology, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Mahony</LastName><ForeName>Liam</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-4705-3583</Identifier><AffiliationInfo><Affiliation>Department of Medicine and School of Microbiology, University College Cork, Cork, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>APC Microbiome Ireland, Cork, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pfaar</LastName><ForeName>Oliver</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0003-4374-9639</Identifier><AffiliationInfo><Affiliation>Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universität Marburg, Marburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Hehir</LastName><ForeName>Robyn</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-3489-7595</Identifier><AffiliationInfo><Affiliation>Allergy, Asthma &amp; Clinical Immunology, The Alfred Hospital, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Immunology, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eiwegger</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Translational Medicine Program, Research Institute, Hospital for Sick Children, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Immunology, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Karl Landsteiner University of Health Sciences, Krems an der Donau, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatric and Adolescent Medicine, University Hospital St. Pölten, St. Pölten, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fokkens</LastName><ForeName>Wytske J</ForeName><Initials>WJ</Initials><Identifier Source="ORCID">0000-0003-4852-229X</Identifier><AffiliationInfo><Affiliation>Department of Otorhinolaryngology &amp; Head and Neck Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cabanillas</LastName><ForeName>Beatriz</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-5351-8140</Identifier><AffiliationInfo><Affiliation>Department of Allergy, Instituto de Investigación Biosanitaria Hospital 12 de Octubre (imas12), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ozdemir</LastName><ForeName>Cevdet</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-9284-4520</Identifier><AffiliationInfo><Affiliation>Department of Pediatric Basic Sciences, Institute of Child Health, Istanbul University, Istanbul, Turkey.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Istanbul Faculty of Medicine, Department of Pediatrics, Division of Pediatric Allergy and Immunology, Istanbul University, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walter</LastName><ForeName>Kistler</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-9289-6953</Identifier><AffiliationInfo><Affiliation>Department of Sports Medicine, Davos Hospital, Davos, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Swiss Research Institute for Sports Medicine (SRISM), Davos, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Committee International Ice Hockey Federation (IIHF), Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bayik</LastName><ForeName>Mahmut</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-3185-8520</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine and Hematology, Marmara University, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nadeau</LastName><ForeName>Kari C</ForeName><Initials>KC</Initials><Identifier Source="ORCID">0000-0002-2146-2955</Identifier><AffiliationInfo><Affiliation>Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torres</LastName><ForeName>Maria J</ForeName><Initials>MJ</Initials><Identifier Source="ORCID">0000-0001-5228-471X</Identifier><AffiliationInfo><Affiliation>Allergy Unit, IBIMA-Hospital Regional Universitario de Málaga-ARADyAL, UMA, Málaga, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akdis</LastName><ForeName>Mübeccel</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-0554-9943</Identifier><AffiliationInfo><Affiliation>Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jutel</LastName><ForeName>Marek</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Clinical Immunology, Wrocław Medical University, Wroclaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agache</LastName><ForeName>Ioana</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0001-7994-364X</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, Department of Allergy and Clinical Immunology, Transylvania University, Brasov, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akdis</LastName><ForeName>Cezmi A</ForeName><Initials>CA</Initials><Identifier Source="ORCID">0000-0001-8020-019X</Identifier><AffiliationInfo><Affiliation>Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Allergy</MedlineTA><NlmUniqueID>7804028</NlmUniqueID><ISSNLinking>0105-4538</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">epidemiology</Keyword><Keyword MajorTopicYN="N">epithelial barrier</Keyword><Keyword MajorTopicYN="N">epithelial barrier dysfunction</Keyword><Keyword MajorTopicYN="N">inflammation</Keyword><Keyword MajorTopicYN="N">microbial dysbiosis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>4</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39370939</ArticleId><ArticleId IdType="doi">10.1111/all.16318</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Akdis CA. Does the epithelial barrier hypothesis explain the increase in allergy, autoimmunity and other chronic conditions? Nat Rev Immunol. 2021;21(11):739‐751.</Citation></Reference><Reference><Citation>D'Amato G, Akdis CA. Desert dust and respiratory diseases: further insights into the epithelial barrier hypothesis. Allergy. 2022;77:3490‐3492.</Citation></Reference><Reference><Citation>Akdis CA. The epithelial barrier hypothesis proposes a comprehensive understanding of the origins of allergic and other chronic noncommunicable diseases. J Allergy Clin Immunol. 2022;149(1):41‐44.</Citation></Reference><Reference><Citation>Pat Y, Ogulur I, Yazici D, et al. Effect of altered human exposome on the skin and mucosal epithelial barrier integrity. Tissue Barriers. 2022;11:2133877.</Citation></Reference><Reference><Citation>Sözener ZC, Cevhertas L, Nadeau K, Akdis M, Akdis CA. Environmental factors in epithelial barrier dysfunction. J Allergy Clin Immunol. 2020;145(6):1517‐1528.</Citation></Reference><Reference><Citation>Wang Z, Walker GW, Muir DC, Nagatani‐Yoshida K. Toward a global understanding of chemical pollution: a first comprehensive analysis of national and regional chemical inventories. Environ Sci Technol. 2020;54(5):2575‐2584.</Citation></Reference><Reference><Citation>Trautmann A, Akdis M, Kleemann D, et al. T cell‐mediated Fas‐induced keratinocyte apoptosis plays a key pathogenetic role in eczematous dermatitis. J Clin Invest. 2000;106(1):25‐35.</Citation></Reference><Reference><Citation>Trautmann A, Schmid‐Grendelmeier P, Kruger K, et al. T cells and eosinophils cooperate in the induction of bronchial epithelial cell apoptosis in asthma. J Allergy Clin Immunol. 2002;109(2):329‐337.</Citation></Reference><Reference><Citation>Basinski TM, Holzmann D, Eiwegger T, et al. Dual nature of T cell‐epithelium interaction in chronic rhinosinusitis. J Allergy Clin Immunol. 2009;124(1):74‐80.e71–78.</Citation></Reference><Reference><Citation>Akdis CA. Allergy and hypersensitivity: mechanisms of allergic disease. Curr Opin Immunol. 2006;18(6):718‐726.</Citation></Reference><Reference><Citation>Akdis M. Healthy immune response to allergens: T regulatory cells and more. Curr Opin Immunol. 2006;18(6):738‐744.</Citation></Reference><Reference><Citation>Xiao C, Puddicombe SM, Field S, et al. Defective epithelial barrier function in asthma. J Allergy Clin Immunol. 2011;128(3):549‐556.e512.</Citation></Reference><Reference><Citation>Soyka MB, Wawrzyniak P, Eiwegger T, et al. Defective epithelial barrier in chronic rhinosinusitis: the regulation of tight junctions by IFN‐γ and IL‐4. J Allergy Clin Immunol. 2012;130(5):1087‐1096.e10.</Citation></Reference><Reference><Citation>Wawrzyniak P, Wawrzyniak M, Wanke K, et al. Regulation of bronchial epithelial barrier integrity by type 2 cytokines and histone deacetylases in asthmatic patients. J Allergy Clin Immunol. 2017;139(1):93‐103.</Citation></Reference><Reference><Citation>Sugita K, Altunbulakli C, Morita H, et al. Human type 2 innate lymphoid cells disrupt skin keratinocyte tight junction barrier by IL‐13. Allergy. 2019;74(12):2534‐2537.</Citation></Reference><Reference><Citation>Xian M, Wawrzyniak P, Ruckert B, et al. Anionic surfactants and commercial detergents decrease tight junction barrier integrity in human keratinocytes. J Allergy Clin Immunol. 2016;138(3):890‐893 e899.</Citation></Reference><Reference><Citation>Altunbulakli C, Reiger M, Neumann AU, et al. Relations between epidermal barrier dysregulation and Staphylococcus species–dominated microbiome dysbiosis in patients with atopic dermatitis. J Allergy Clin Immunol. 2018;142(5):1643‐1647.e12.</Citation></Reference><Reference><Citation>Wang M, Tan G, Eljaszewicz A, et al. Laundry detergents and detergent residue after rinsing directly disrupt tight junction barrier integrity in human bronchial epithelial cells. J Allergy Clin Immunol. 2019;143(5):1892‐1903.</Citation></Reference><Reference><Citation>Xian M, Ma S, Wang K, et al. Particulate matter 2.5 causes deficiency in barrier integrity in human nasal epithelial cells. Allergy, Asthma Immunol Res. 2020;12(1):56‐71.</Citation></Reference><Reference><Citation>Michaudel C, Mackowiak C, Maillet I, et al. Ozone exposure induces respiratory barrier biphasic injury and inflammation controlled by IL‐33. J Allergy Clin Immunol. 2018;142(3):942‐958.</Citation></Reference><Reference><Citation>Jin Y, Lu L, Tu W, Luo T, Fu Z. Impacts of polystyrene microplastic on the gut barrier, microbiota and metabolism of mice. Sci Total Environ. 2019;649:308‐317.</Citation></Reference><Reference><Citation>Ogulur I, Pat Y, Aydin T, et al. Gut epithelial barrier damage caused by dishwasher detergents and rinse aids. J Allergy Clin Immunol. 2023;151(2):469‐484.</Citation></Reference><Reference><Citation>Ogulur I, Yazici D, Pat Y, et al. Mechanisms of gut epithelial barrier impairment caused by food emulsifiers polysorbate 20 and polysorbate 80. Allergy. 2023;78(9):2441‐2455.</Citation></Reference><Reference><Citation>Rinaldi AO, Li M, Barletta E, et al. Household laundry detergents disrupt barrier integrity and induce inflammation in mouse and human skin. Allergy. 2024;79(1):128‐141.</Citation></Reference><Reference><Citation>Mitamura Y, Ogulur I, Pat Y, et al. Dysregulation of the epithelial barrier by environmental and other exogenous factors. Contact Derm. 2021;85(6):615‐626.</Citation></Reference><Reference><Citation>Kiykim A, Ogulur I, Yazici D, Cokugras H, Akdis M, Akdis CA. Epithelial barrier hypothesis and its comparison with the hygiene hypothesis. Turk Arch Pediatr. 2023;58(2):122‐128.</Citation></Reference><Reference><Citation>Moens E, Veldhoen M. Epithelial barrier biology: good fences make good neighbours. Immunology. 2012;135(1):1‐8.</Citation></Reference><Reference><Citation>Eyerich S, Eyerich K, Traidl‐Hoffmann C, Biedermann T. Cutaneous barriers and skin immunity: differentiating a connected network. Trends Immunol. 2018;39(4):315‐327.</Citation></Reference><Reference><Citation>Hellings PW, Steelant B. Epithelial barriers in allergy and asthma. J Allergy Clin Immunol. 2020;145(6):1499‐1509.</Citation></Reference><Reference><Citation>Zhou A, Yuan Y, Yang M, et al. Crosstalk between the gut microbiota and epithelial cells under physiological and infectious conditions. Front Cell Infect Microbiol. 2022;12:23.</Citation></Reference><Reference><Citation>Gaboriau‐Routhiau V, Rakotobe S, Lecuyer E, et al. The key role of segmented filamentous bacteria in the coordinated maturation of gut helper T cell responses. Immunity. 2009;31(4):677‐689.</Citation></Reference><Reference><Citation>Ivanov II, Atarashi K, Manel N, et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell. 2009;139(3):485‐498.</Citation></Reference><Reference><Citation>Martin‐Gallausiaux C, Marinelli L, Blottière HM, Larraufie P, Lapaque N. SCFA: mechanisms and functional importance in the gut. Proc Nutr Soc. 2021;80(1):37‐49.</Citation></Reference><Reference><Citation>Vinolo MA, Rodrigues HG, Nachbar RT, Curi R. Regulation of inflammation by short chain fatty acids. Nutrients. 2011;3(10):858‐876.</Citation></Reference><Reference><Citation>Kast JI, McFarlane AJ, Globinska A, et al. Respiratory syncytial virus infection influences tight junction integrity. Clin Exp Immunol. 2017;190(3):351‐359.</Citation></Reference><Reference><Citation>Tan HT, Hagner S, Ruchti F, et al. Tight junction, mucin, and inflammasome‐related molecules are differentially expressed in eosinophilic, mixed, and neutrophilic experimental asthma in mice. Allergy. 2019;74(2):294‐307.</Citation></Reference><Reference><Citation>Radzikowska U, Eljaszewicz A, Tan G, et al. Rhinovirus‐induced epithelial RIG‐I inflammasome suppresses antiviral immunity and promotes inflammation in asthma and COVID‐19. Nat Commun. 2023;14(1):2329.</Citation></Reference><Reference><Citation>Stocker N, Radzikowska U, Wawrzyniak P, et al. Regulation of angiotensin‐converting enzyme 2 isoforms by type 2 inflammation and viral infection in human airway epithelium. Mucosal Immunol. 2023;16(1):5‐16.</Citation></Reference><Reference><Citation>Aghapour M, Raee P, Moghaddam SJ, Hiemstra PS, Heijink IH. Airway epithelial barrier dysfunction in chronic obstructive pulmonary disease: role of cigarette smoke exposure. Am J Respir Cell Mol Biol. 2018;58(2):157‐169.</Citation></Reference><Reference><Citation>Feldman C, Anderson R. Cigarette smoking and mechanisms of susceptibility to infections of the respiratory tract and other organ systems. J Infect. 2013;67(3):169‐184.</Citation></Reference><Reference><Citation>Radzikowska U, Ding M, Tan G, et al. Distribution of ACE2, CD147, CD26, and other SARS‐CoV‐2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID‐19 risk factors. Allergy. 2020;75(11):2829‐2845.</Citation></Reference><Reference><Citation>Gon Y, Hashimoto S. Role of airway epithelial barrier dysfunction in pathogenesis of asthma. Allergol Int. 2018;67(1):12‐17.</Citation></Reference><Reference><Citation>Akdis M, Burgler S, Crameri R, et al. Interleukins, from 1 to 37, and interferon‐gamma: receptors, functions, and roles in diseases. J Allergy Clin Immunol. 2011;127(3):701‐721.e1‐70.</Citation></Reference><Reference><Citation>Eljaszewicz A, Ruchti F, Radzikowska U, et al. Trained immunity and tolerance in innate lymphoid cells, monocytes, and dendritic cells during allergen‐specific immunotherapy. J Allergy Clin Immunol. 2021;147(5):1865‐1877.</Citation></Reference><Reference><Citation>Kezic S, O'Regan GM, Lutter R, et al. Filaggrin loss‐of‐function mutations are associated with enhanced expression of IL‐1 cytokines in the stratum corneum of patients with atopic dermatitis and in a murine model of filaggrin deficiency. J Allergy Clin Immunol. 2012;129(4):1031‐1039.e1.</Citation></Reference><Reference><Citation>Yoshida K, Kubo A, Fujita H, et al. Distinct behavior of human Langerhans cells and inflammatory dendritic epidermal cells at tight junctions in patients with atopic dermatitis. J Allergy Clin Immunol. 2014;134(4):856‐864.</Citation></Reference><Reference><Citation>Czarnowicki T, Krueger JG, Guttman‐Yassky E. Novel concepts of prevention and treatment of atopic dermatitis through barrier and immune manipulations with implications for the atopic march. J Allergy Clin Immunol. 2017;139(6):1723‐1734.</Citation></Reference><Reference><Citation>Lambrecht BN, Hammad H. The airway epithelium in asthma. Nat Med. 2012;18(5):684‐692.</Citation></Reference><Reference><Citation>Loxham M, Davies D, Blume C. Epithelial function and dysfunction in asthma. Clin Exp Allergy. 2014;44(11):1299‐1313.</Citation></Reference><Reference><Citation>Gold MJ, Antignano F, Halim TY, et al. Group 2 innate lymphoid cells facilitate sensitization to local, but not systemic, TH2‐inducing allergen exposures. J Allergy Clin Immunol. 2014;133(4):1142‐1148.</Citation></Reference><Reference><Citation>Dong X, Ding M, Zhang J, et al. Involvement and therapeutic implications of airway epithelial barrier dysfunction in type 2 inflammation of asthma. Chin Med J. 2022;135(05):519‐531.</Citation></Reference><Reference><Citation>Gillespie MR, Rai V, Agrawal S, Nandipati KC. The role of microbiota in the pathogenesis of esophageal adenocarcinoma. Biology (Basel). 2021;10(8):697.</Citation></Reference><Reference><Citation>Novak N, Haberstok J, Bieber T, Allam J‐P. The immune privilege of the oral mucosa. Trends Mol Med. 2008;14(5):191‐198.</Citation></Reference><Reference><Citation>Kaymak T, Hruz P, Niess JH. Immune system and microbiome in the esophagus: implications for understanding inflammatory diseases. FEBS J. 2022;289(16):4758‐4772.</Citation></Reference><Reference><Citation>Goto Y, Kiyono H. Epithelial barrier: an interface for the cross‐communication between gut flora and immune system. Immunol Rev. 2012;245(1):147‐163.</Citation></Reference><Reference><Citation>Mowat AM, Agace WW. Regional specialization within the intestinal immune system. Nat Rev Immunol. 2014;14(10):667‐685.</Citation></Reference><Reference><Citation>McDole JR, Wheeler LW, McDonald KG, et al. Goblet cells deliver luminal antigen to CD103+ dendritic cells in the small intestine. Nature. 2012;483(7389):345‐349.</Citation></Reference><Reference><Citation>Zeuthen LH, Fink LN, Frokiaer H. Epithelial cells prime the immune response to an array of gut‐derived commensals towards a tolerogenic phenotype through distinct actions of thymic stromal lymphopoietin and transforming growth factor‐β. Immunology. 2008;123(2):197‐208.</Citation></Reference><Reference><Citation>Rimoldi M, Chieppa M, Salucci V, et al. Intestinal immune homeostasis is regulated by the crosstalk between epithelial cells and dendritic cells. Nat Immunol. 2005;6(5):507‐514.</Citation></Reference><Reference><Citation>Von Moltke J, Ji M, Liang H‐E, Locksley RM. Tuft‐cell‐derived IL‐25 regulates an intestinal ILC2–epithelial response circuit. Nature. 2016;529(7585):221‐225.</Citation></Reference><Reference><Citation>Moro K, Yamada T, Tanabe M, et al. Innate production of TH2 cytokines by adipose tissue‐associated c‐Kit+ Sca‐1+ lymphoid cells. Nature. 2010;463(7280):540‐544.</Citation></Reference><Reference><Citation>Humphreys NE, Xu D, Hepworth MR, Liew FY, Grencis RK. IL‐33, a potent inducer of adaptive immunity to intestinal nematodes. J Immunol. 2008;180(4):2443‐2449.</Citation></Reference><Reference><Citation>Tobacman JK. Review of harmful gastrointestinal effects of carrageenan in animal experiments. Environ Health Perspect. 2001;109(10):983‐994.</Citation></Reference><Reference><Citation>Chassaing B, Koren O, Goodrich JK, et al. Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome. Nature. 2015;519(7541):92‐96.</Citation></Reference><Reference><Citation>Chigbu D, Minhas BK. Immunopathology of allergic conjunctivitis. Eur Med J. 2018;3:76‐83.</Citation></Reference><Reference><Citation>Singh N, Diebold Y, Sahu SK, Leonardi A. Epithelial barrier dysfunction in ocular allergy. Allergy. 2022;77(5):1360‐1372.</Citation></Reference><Reference><Citation>Hu J, Gao N, Zhang Y, et al. IL‐33/ST2/IL‐9/IL‐9R signaling disrupts ocular surface barrier in allergic inflammation. Mucosal Immunol. 2020;13(6):919‐930.</Citation></Reference><Reference><Citation>Zheng X, Ma P, de Paiva CS, et al. TSLP and downstream molecules in experimental mouse allergic conjunctivitis. Invest Ophthalmol Vis Sci. 2010;51(6):3076‐3082.</Citation></Reference><Reference><Citation>Takai T. TSLP expression: cellular sources, triggers, and regulatory mechanisms. Allergol Int. 2012;61(1):3‐17.</Citation></Reference><Reference><Citation>Uberoi A, Bartow‐McKenney C, Zheng Q, et al. Commensal microbiota regulates skin barrier function and repair via signaling through the aryl hydrocarbon receptor. Cell Host Microbe. 2021;29(8):1235‐1248.e8.</Citation></Reference><Reference><Citation>Belkaid Y, Segre JA. Dialogue between skin microbiota and immunity. Science. 2014;346(6212):954‐959.</Citation></Reference><Reference><Citation>Spergel JM, Paller AS. Atopic dermatitis and the atopic march. J Allergy Clin Immunol. 2003;112(6):S118‐S127.</Citation></Reference><Reference><Citation>Silverberg JI. Persistence of childhood eczema into adulthood. JAMA Dermatol. 2014;150(6):591‐592.</Citation></Reference><Reference><Citation>Spergel JM. Epidemiology of atopic dermatitis and atopic march in children. Immunol Allergy Clin. 2010;30(3):269‐280.</Citation></Reference><Reference><Citation>Silverberg J. Association between adult atopic dermatitis, cardiovascular disease, and increased heart attacks in three population‐based studies. Allergy. 2015;70(10):1300‐1308.</Citation></Reference><Reference><Citation>Andersen YM, Egeberg A, Gislason GH, Hansen PR, Skov L, Thyssen JP. Risk of myocardial infarction, ischemic stroke, and cardiovascular death in patients with atopic dermatitis. J Allergy Clin Immunol. 2016;138(1):310‐312.e3.</Citation></Reference><Reference><Citation>Olesen AB, Bang K, Juul S, Thestrup‐Pedersen K. Stable incidence of atopic dermatitis among children in Denmark during the 1990s. Acta Derm Venereol. 2005;1(1):1.</Citation></Reference><Reference><Citation>Reijula J, Latvala J, Mäkelä M, Siitonen S, Saario M, Haahtela T. Long‐term trends of asthma, allergic rhinitis and atopic eczema in young Finnish men: a retrospective analysis, 1926–2017. Eur Respir J. 2020;56(6):1902144.</Citation></Reference><Reference><Citation>Agrawal R, Woodfolk JA. Skin barrier defects in atopic dermatitis. Curr Allergy Asthma Rep. 2014;14:1‐11.</Citation></Reference><Reference><Citation>Irvine AD, McLean WI, Leung DY. Filaggrin mutations associated with skin and allergic diseases. New Engl J Med. 2011;365(14):1315‐1327.</Citation></Reference><Reference><Citation>Leung DY, Berdyshev E, Goleva E. Cutaneous barrier dysfunction in allergic diseases. J Allergy Clin Immunol. 2020;145(6):1485‐1497.</Citation></Reference><Reference><Citation>Palmer CN, Irvine AD, Terron‐Kwiatkowski A, et al. Common loss‐of‐function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet. 2006;38(4):441‐446.</Citation></Reference><Reference><Citation>De Benedetto A, Rafaels NM, McGirt LY, et al. Tight junction defects in patients with atopic dermatitis. J Allergy Clin Immunol. 2011;127(3):773‐786.e1–7.</Citation></Reference><Reference><Citation>Rinaldi AO, Korsfeldt A, Ward S, et al. Electrical impedance spectroscopy for the characterization of skin barrier in atopic dermatitis. Allergy. 2021;76(10):3066‐3079.</Citation></Reference><Reference><Citation>Çetinarslan T, Kümper L, Fölster‐Holst R. The immunological and structural epidermal barrier dysfunction and skin microbiome in atopic dermatitis‐an update. Front Mol Biosci. 2023;10:1159404.</Citation></Reference><Reference><Citation>Spergel JM. From atopic dermatitis to asthma: the atopic march. Ann Allergy Asthma Immunol. 2010;105(2):99‐106.</Citation></Reference><Reference><Citation>Brunner PM, Suárez‐Fariñas M, He H, et al. The atopic dermatitis blood signature is characterized by increases in inflammatory and cardiovascular risk proteins. Sci Rep. 2017;7(1):8707.</Citation></Reference><Reference><Citation>Vano‐Galvan S, Egeberg A, Piraccini BM, et al. Characteristics and management of patients with alopecia Areata and selected comorbid conditions: results from a survey in five European countries. Dermatol Ther (Heidelb). 2024;14(4):1027‐1037.</Citation></Reference><Reference><Citation>Kridin K, Renert‐Yuval Y, Guttman‐Yassky E, Cohen AD. Alopecia areata is associated with atopic diathesis: results from a population‐based study of 51,561 patients. J Allergy Clin Immunol Pract. 2020;8(4):1323‐1328 e1321.</Citation></Reference><Reference><Citation>Thyssen JP, Halling AS, Schmid‐Grendelmeier P, Guttman‐Yassky E, Silverberg JI. Comorbidities of atopic dermatitis‐what does the evidence say? J Allergy Clin Immunol. 2023;151(5):1155‐1162.</Citation></Reference><Reference><Citation>Guttman‐Yassky E, Renert‐Yuval Y, Bares J, et al. Phase 2a randomized clinical trial of dupilumab (anti‐IL‐4Ralpha) for alopecia areata patients. Allergy. 2022;77(3):897‐906.</Citation></Reference><Reference><Citation>Song T, Guttman‐Yassky E. Alopecia areata: a complex cytokine driven disease. J Investig Dermatol Symp Proc. 2020;20(1):S55‐S57.</Citation></Reference><Reference><Citation>Kaplan DH, Igyártó BZ, Gaspari AA. Early immune events in the induction of allergic contact dermatitis. Nat Rev Immunol. 2012;12(2):114‐124.</Citation></Reference><Reference><Citation>Jutel M, Agache I, Zemelka‐Wiacek M, et al. Nomenclature of allergic diseases and hypersensitivity reactions: adapted to modern needs: an EAACI position paper. Allergy. 2023;78(11):2851‐2874.</Citation></Reference><Reference><Citation>McFadden J, Puangpet P, Basketter D, Dearman R, Kimber I. Why does allergic contact dermatitis exist? Br J Dermatol. 2013;168(4):692‐699.</Citation></Reference><Reference><Citation>Martin SF. New concepts in cutaneous allergy. Contact Derm. 2015;72(1):2‐10.</Citation></Reference><Reference><Citation>Pavel AB, Del Duca E, Cheng J, et al. Delayed type hypersensitivity reactions to various allergens may differently model inflammatory skin diseases. Allergy. 2023;78(1):178‐191.</Citation></Reference><Reference><Citation>Bregnbak D, Johansen JD, Jellesen MS, Zachariae C, Menné T, Thyssen JP. Chromium allergy and dermatitis: prevalence and main findings. Contact Derm. 2015;73(5):261‐280.</Citation></Reference><Reference><Citation>Thyssen JP, Johansen JD, Menné T. Contact allergy epidemics and their controls. Contact Derm. 2007;56(4):185‐195.</Citation></Reference><Reference><Citation>Novak N, Baurecht H, Schäfer T, et al. Loss‐of‐function mutations in the filaggrin gene and allergic contact sensitization to nickel. J Invest Dermatol. 2008;128(6):1430‐1435.</Citation></Reference><Reference><Citation>Proksch E, Brasch J. Abnormal epidermal barrier in the pathogenesis of contact dermatitis. Clin Dermatol. 2012;30(3):335‐344.</Citation></Reference><Reference><Citation>Thyssen JP, Linneberg A, Ross‐Hansen K, et al. Filaggrin mutations are strongly associated with contact sensitization in individuals with dermatitis. Contact Derm. 2013;68(5):273‐276.</Citation></Reference><Reference><Citation>Meisser SS, Altunbulakli C, Bandier J, et al. Skin barrier damage after exposure to paraphenylenediamine. J Allergy Clin Immunol. 2020;145(2):619‐631. e612.</Citation></Reference><Reference><Citation>Mäenpää K, Wang S, Ilves M, et al. Skin microbiota of oxazolone‐induced contact hypersensitivity mouse model. PLoS One. 2022;17(10):e0276071.</Citation></Reference><Reference><Citation>Patel K, Nixon R. Irritant contact dermatitis ‐ a review. Curr Dermatol Rep. 2022;11(2):41‐51.</Citation></Reference><Reference><Citation>Shibuya R, Ishida Y, Hanakawa S, et al. CCL2–CCR2 signaling in the skin drives surfactant‐induced irritant contact dermatitis through IL‐1beta–mediated neutrophil accumulation. J Invest Dermatol. 2022;142(3 Pt A):571‐582.e9.</Citation></Reference><Reference><Citation>Stocks SJ, McNamee R, Turner S, Carder M, Agius RM. The impact of national‐level interventions to improve hygiene on the incidence of irritant contact dermatitis in healthcare workers: changes in incidence from 1996 to 2012 and interrupted times series analysis. Br J Dermatol. 2015;173(1):165‐171.</Citation></Reference><Reference><Citation>Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018;73(7):1393‐1414.</Citation></Reference><Reference><Citation>Bracken SJ, Abraham S, MacLeod AS. Autoimmune theories of chronic spontaneous urticaria. Front Immunol. 2019;10:627.</Citation></Reference><Reference><Citation>Lapi F, Cassano N, Pegoraro V, et al. Epidemiology of chronic spontaneous urticaria: results from a nationwide, population‐based study in Italy. Br J Dermatol. 2016;174(5):996‐1004.</Citation></Reference><Reference><Citation>Giménez‐Arnau A, Curto‐Barredo L, Nonell L, et al. Transcriptome analysis of severely active chronic spontaneous urticaria shows an overall immunological skin involvement. Allergy. 2017;72(11):1778‐1790.</Citation></Reference><Reference><Citation>Ye Y‐M, Kim BE, Shin YS, Park H‐S, Leung DY. Increased epidermal filaggrin in chronic idiopathic urticaria is associated with severity of urticaria. Ann Allergy Asthma Immunol. 2014;112(6):533‐538.</Citation></Reference><Reference><Citation>Gschwandtner M, Mildner M, Mlitz V, et al. Histamine suppresses epidermal keratinocyte differentiation and impairs skin barrier function in a human skin model. Allergy. 2013;68(1):37‐47.</Citation></Reference><Reference><Citation>Lin W, Zhou Q, Liu C, Ying M, Xu S. Increased plasma IL‐17, IL‐31, and IL‐33 levels in chronic spontaneous urticaria. Sci Rep. 2017;7(1):1‐6.</Citation></Reference><Reference><Citation>Kay A, Clark P, Maurer M, Ying S. Elevations in T‐helper‐2‐initiating cytokines (interleukin‐33, interleukin‐25 and thymic stromal lymphopoietin) in lesional skin from chronic spontaneous (‘idiopathic’) urticaria. Br J Dermatol. 2015;172(5):1294‐1302.</Citation></Reference><Reference><Citation>Nabizadeh E, Jazani NH, Bagheri M, Shahabi S. Association of altered gut microbiota composition with chronic urticaria. Ann Allergy Asthma Immunol. 2017;119(1):48‐53.</Citation></Reference><Reference><Citation>Candela M, Rampelli S, Turroni S, et al. Unbalance of intestinal microbiota in atopic children. BMC Microbiol. 2012;12(1):1‐9.</Citation></Reference><Reference><Citation>Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature. 2007;445(7130):866‐873.</Citation></Reference><Reference><Citation>Rendon A, Schäkel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019;20(6):1475.</Citation></Reference><Reference><Citation>Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377‐385.</Citation></Reference><Reference><Citation>Icen M, Crowson CS, McEvoy MT, Dann FJ, Gabriel SE, Kremers HM. Trends in incidence of adult‐onset psoriasis over three decades: a population‐based study. J Am Acad Dermatol. 2009;60(3):394‐401.</Citation></Reference><Reference><Citation>Eder L, Widdifield J, Rosen CF, et al. Trends in the prevalence and incidence of psoriasis and psoriatic arthritis in Ontario, Canada: a population‐based study. Arthritis Care Res. 2019;71(8):1084‐1091.</Citation></Reference><Reference><Citation>Kim J, Krueger JG. Highly effective new treatments for psoriasis target the IL‐23/type 17 T cell autoimmune axis. Annu Rev Med. 2017;68:255‐269.</Citation></Reference><Reference><Citation>Wohn C, Ober‐Blöbaum JL, Haak S, et al. Langerinneg conventional dendritic cells produce IL‐23 to drive psoriatic plaque formation in mice. Proc Natl Acad Sci. 2013;110(26):10723‐10728.</Citation></Reference><Reference><Citation>Van Der Fits L, Mourits S, Voerman JS, et al. Imiquimod‐induced psoriasis‐like skin inflammation in mice is mediated via the IL‐23/IL‐17 axis. J Immunol. 2009;182(9):5836‐5845.</Citation></Reference><Reference><Citation>Lowes MA, Suarez‐Farinas M, Krueger JG. Immunology of psoriasis. Annu Rev Immunol. 2014;32:227.</Citation></Reference><Reference><Citation>Wongjirattikarn R, Chaisuriya N, Chaowattanapanit S, et al. Increased tissue expression of IL‐31 in patients with psoriasis. Cytokine. 2024;176:156531.</Citation></Reference><Reference><Citation>Yuki T, Tobiishi M, Kusaka‐Kikushima A, Ota Y, Tokura Y. Impaired tight junctions in atopic dermatitis skin and in a skin‐equivalent model treated with interleukin‐17. PLoS One. 2016;11(9):e0161759.</Citation></Reference><Reference><Citation>Gutowska‐Owsiak D, Schaupp AL, Salimi M, et al. IL‐17 downregulates filaggrin and affects keratinocyte expression of genes associated with cellular adhesion. Exp Dermatol. 2012;21(2):104‐110.</Citation></Reference><Reference><Citation>Grice K, Sattar H, Baker H. The cutaneous barrier to salts and water in psoriasis and in normal skin. Br J Dermatol. 1973;88(5):459‐463.</Citation></Reference><Reference><Citation>Motta S, Monti M, Sesana S, Mellesi L, Ghidoni R, Caputo R. Abnormality of water barrier function in psoriasis: role of ceramide fractions. Arch Dermatol. 1994;130(4):452‐456.</Citation></Reference><Reference><Citation>Takahashi H, Tsuji H, Minami‐Hori M, Miyauchi Y, Iizuka H. Defective barrier function accompanied by structural changes of psoriatic stratum corneum. J Dermatol. 2014;41(2):144‐148.</Citation></Reference><Reference><Citation>Yan D, Issa N, Afifi L, Jeon C, Chang H‐W, Liao W. The role of the skin and gut microbiome in psoriatic disease. Curr Dermatol Rep. 2017;6(2):94‐103.</Citation></Reference><Reference><Citation>Alekseyenko AV, Perez‐Perez GI, De Souza A, et al. Community differentiation of the cutaneous microbiota in psoriasis. Microbiome. 2013;1(1):1‐17.</Citation></Reference><Reference><Citation>Fahlén A, Engstrand L, Baker BS, Powles A, Fry L. Comparison of bacterial microbiota in skin biopsies from normal and psoriatic skin. Arch Dermatol Res. 2012;304(1):15‐22.</Citation></Reference><Reference><Citation>Drago L, De Grandi R, Altomare G, Pigatto P, Rossi O, Toscano M. Skin microbiota of first cousins affected by psoriasis and atopic dermatitis. Clin Mol Allergy. 2016;14(1):1‐11.</Citation></Reference><Reference><Citation>Dekio I, Hayashi H, Sakamoto M, et al. Detection of potentially novel bacterial components of the human skin microbiota using culture‐independent molecular profiling. J Med Microbiol. 2005;54(12):1231‐1238.</Citation></Reference><Reference><Citation>Smith PM, Howitt MR, Panikov N, et al. The microbial metabolites, short‐chain fatty acids, regulate colonic Treg cell homeostasis. Science. 2013;341(6145):569‐573.</Citation></Reference><Reference><Citation>Round JL, Mazmanian SK. The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol. 2009;9(5):313‐323.</Citation></Reference><Reference><Citation>Gao Z, Tseng C‐h, Strober BE, Pei Z, Blaser MJ. Substantial alterations of the cutaneous bacterial biota in psoriatic lesions. PLoS One. 2008;3(7):e2719.</Citation></Reference><Reference><Citation>Borradori L, Van Beek N, Feliciani C, et al. Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European academy of dermatology and venereology (EADV). J Eur Acad Dermatol Venereol. 2022;36(10):1689‐1704.</Citation></Reference><Reference><Citation>Brick KE, Weaver CH, Lohse CM, et al. Incidence of bullous pemphigoid and mortality of patients with bullous pemphigoid in Olmsted County, Minnesota, 1960 through 2009. J Am Acad Dermatol. 2014;71(1):92‐99.</Citation></Reference><Reference><Citation>Joly P, Baricault S, Sparsa A, et al. Incidence and mortality of bullous pemphigoid in France. J Invest Dermatol. 2012;132(8):1998‐2004.</Citation></Reference><Reference><Citation>Hammers CM, Stanley JR. Mechanisms of disease: pemphigus and bullous pemphigoid. Annu Rev Pathol. 2016;11:175.</Citation></Reference><Reference><Citation>Hu Y‐q, Zhang J‐z. A comparison for type 2 cytokines and lesional inflammatory infiltrations in bullous pemphigoid and atopic dermatitis. Clin, Cosmetic Invest Dermatol. 2022;15:2313‐2321.</Citation></Reference><Reference><Citation>Miodovnik M, Künstner A, Langan EA, et al. A distinct cutaneous microbiota profile in autoimmune bullous disease patients. Exp Dermatol. 2017;26(12):1221‐1227.</Citation></Reference><Reference><Citation>Belheouane M, Hermes BM, Van Beek N, et al. Characterization of the skin microbiota in bullous pemphigoid patients and controls reveals novel microbial indicators of disease. J Adv Res. 2022;44:71‐79.</Citation></Reference><Reference><Citation>de Oliveira ASLE, Bloise G, Moltrasio C, et al. Transcriptome meta‐analysis confirms the hidradenitis suppurativa pathogenic triad: upregulated inflammation, altered epithelial organization, and dysregulated metabolic signaling. Biomol Ther. 2022;12(10):1371.</Citation></Reference><Reference><Citation>Schell SL, Schneider AM, Nelson AM. Yin and Yang: a disrupted skin microbiome and an aberrant host immune response in hidradenitis suppurativa. Exp Dermatol. 2021;30(10):1453‐1470.</Citation></Reference><Reference><Citation>Revuz JE, Canoui‐Poitrine F, Wolkenstein P, et al. Prevalence and factors associated with hidradenitis suppurativa: results from two case‐control studies. J Am Acad Dermatol. 2008;59(4):596‐601.</Citation></Reference><Reference><Citation>Sartorius K, Emtestam L, Jemec G, Lapins J. Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity. Br J Dermatol. 2009;161(4):831‐839.</Citation></Reference><Reference><Citation>Van der Zee H, Van Der Woude C, Florencia E, Prens E. Hidradenitis suppurativa and inflammatory bowel disease: are they associated? Results of a pilot study. Br J Dermatol. 2010;162(1):195‐197.</Citation></Reference><Reference><Citation>Vazquez BG, Alikhan A, Weaver AL, Wetter DA, Davis MD. Incidence of hidradenitis suppurativa and associated factors: a population‐based study of Olmsted County, Minnesota. J Invest Dermatol. 2013;133(1):97‐103.</Citation></Reference><Reference><Citation>Lowe MM, Naik HB, Clancy S, et al. Immunopathogenesis of hidradenitis suppurativa and response to anti–TNF‐α therapy. JCI Insight. 2020;5(19):e139932.</Citation></Reference><Reference><Citation>Witte‐Händel E, Wolk K, Tsaousi A, et al. The IL‐1 pathway is hyperactive in hidradenitis suppurativa and contributes to skin infiltration and destruction. J Invest Dermatol. 2019;139(6):1294‐1305.</Citation></Reference><Reference><Citation>Zouboulis CC, Nogueira da Costa A, Makrantonaki E, et al. Alterations in innate immunity and epithelial cell differentiation are the molecular pillars of hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2020;34(4):846‐861.</Citation></Reference><Reference><Citation>Kurokawa I, Nishijima S, Kusumoto K, Senzaki H, Shikata N, Tsubura A. Immunohistochemical study of cytokeratins in hidradenitis suppurativa (acne inversa). J Int Med Res. 2002;30(2):131‐136.</Citation></Reference><Reference><Citation>Blok JL, Janse IC, Horváth B, Jonkman MF. Increased expression of integrin α6β4 in the basement membrane zone lining the sebaceous glands in hidradenitis suppurativa. Acta Derm Venereol. 2015;95(8):994‐996.</Citation></Reference><Reference><Citation>Kurzen H, Jung E, Hartschuh W, Moll I, Franke W, Moll R. Forms of epithelial differentiation of draining sinus in acne inversa (hidradenitis suppurativa). Br J Dermatol. 1999;141(2):231‐239.</Citation></Reference><Reference><Citation>Nelson AM, Cong Z, Gettle SL, et al. E‐cadherin and p120ctn protein expression are lost in hidradenitis suppurativa lesions. Exp Dermatol. 2019;28(7):867‐871.</Citation></Reference><Reference><Citation>Mintoff D, Benhadou F, Pace NP, Frew JW. Metabolic syndrome and hidradenitis suppurativa: epidemiological, molecular, and therapeutic aspects. Int J Dermatol. 2022;61(10):1175‐1186.</Citation></Reference><Reference><Citation>Shalom G, Freud T, Harman‐Boehm I, Polishchuk I, Cohen A. Hidradenitis suppurativa and metabolic syndrome: a comparative cross‐sectional study of 3207 patients. Br J Dermatol. 2015;173(2):464‐470.</Citation></Reference><Reference><Citation>Kikkert R, Laine M, Aarden L, Van Winkelhoff A. Activation of toll‐like receptors 2 and 4 by gram‐negative periodontal bacteria. Oral Microbiol Immunol. 2007;22(3):145‐151.</Citation></Reference><Reference><Citation>Schick J, Etschel P, Bailo R, et al. Toll‐like receptor 2 and Mincle cooperatively sense corynebacterial cell wall glycolipids. Infect Immun. 2017;85(7):e00075‐00017.</Citation></Reference><Reference><Citation>Jang H‐M, Park J‐Y, Lee Y‐J, et al. TLR2 and the NLRP3 inflammasome mediate IL‐1β production in Prevotella nigrescens‐infected dendritic cells. Int J Med Sci. 2021;18(2):432.</Citation></Reference><Reference><Citation>Hunger R, Surovy AM, Hassan A, Braathen L, Yawalkar N. Toll‐like receptor 2 is highly expressed in lesions of acne inversa and colocalizes with C‐type lectin receptor. Br J Dermatol. 2008;158(4):691‐697.</Citation></Reference><Reference><Citation>Aghapour M, Ubags ND, Bruder D, et al. Role of air pollutants in airway epithelial barrier dysfunction in asthma and COPD. Eur Respir Rev. 2022;31(163):210112.</Citation></Reference><Reference><Citation>Asher MI, García‐Marcos L, Pearce NE, Strachan DP. Trends in worldwide asthma prevalence. Eur Respir J. 2020;56(6):2002094.</Citation></Reference><Reference><Citation>Collaborators GCRD. Global, regional, and national deaths, prevalence, disability‐adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the global burden of disease study 2015. Lancet Respir Med. 2017;5(9):691.</Citation></Reference><Reference><Citation>Haahtela T, Lindholm H, Björkstén F, Koskenvuo K, Laitinen L. Prevalence of asthma in Finnish young men. Br Med J. 1990;301(6746):266‐268.</Citation></Reference><Reference><Citation>Anderson HR, Gupta R, Strachan DP, Limb ES. 50 years of asthma: UK trends from 1955 to 2004. Thorax. 2007;62(1):85‐90.</Citation></Reference><Reference><Citation>Akdis CA, Arkwright PD, Brüggen M‐C, et al. Type 2 immunity in the skin and lungs. Allergy. 2020;75(7):1582‐1605.</Citation></Reference><Reference><Citation>Gao H, Ying S, Dai Y. Pathological roles of neutrophil‐mediated inflammation in asthma and its potential for therapy as a target. J Immunol Res. 2017;2017(1):3743048.</Citation></Reference><Reference><Citation>de Boer WI, Sharma HS, Baelemans SM, Hoogsteden HC, Lambrecht BN, Braunstahl GJ. Altered expression of epithelial junctional proteins in atopic asthma: possible role in inflammation. Can J Physiol Pharmacol. 2008;86(3):105‐112.</Citation></Reference><Reference><Citation>Sweerus K, Lachowicz‐Scroggins M, Gordon E, et al. Claudin‐18 deficiency is associated with airway epithelial barrier dysfunction and asthma. J Allergy Clin Immunol. 2017;139(1):72‐81.e1.</Citation></Reference><Reference><Citation>Chung KF. Airway microbial dysbiosis in asthmatic patients: a target for prevention and treatment? J Allergy Clin Immunol. 2017;139(4):1071‐1081.</Citation></Reference><Reference><Citation>Davis MF, Peng RD, McCormack MC, Matsui EC. Staphylococcus aureus colonization is associated with wheeze and asthma among US children and young adults. J Allergy Clin Immunol. 2015;135(3):811‐813.e5.</Citation></Reference><Reference><Citation>Hilty M, Burke C, Pedro H, et al. Disordered microbial communities in asthmatic airways. PLoS One. 2010;5(1):e8578.</Citation></Reference><Reference><Citation>Barcik W, Pugin B, Westermann P, et al. Histamine‐secreting microbes are increased in the gut of adult asthma patients. J Allergy Clin Immunol. 2016;138(5):1491‐1494.e7.</Citation></Reference><Reference><Citation>Michalovich D, Rodriguez‐Perez N, Smolinska S, et al. Obesity and disease severity magnify disturbed microbiome‐immune interactions in asthma patients. Nat Commun. 2019;10(1):5711.</Citation></Reference><Reference><Citation>Roduit C, Frei R, Ferstl R, et al. High levels of butyrate and propionate in early life are associated with protection against atopy. Allergy. 2019;74(4):799‐809.</Citation></Reference><Reference><Citation>Bousquet J, Anto JM, Bachert C, et al. Allergic rhinitis. Nat Rev Dis Prim. 2020;6(1):95.</Citation></Reference><Reference><Citation>Bousquet J, Khaltaev N, Cruz AA, et al. Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA2LEN and AllerGen). Allergy. 2008;63(86):8‐160.</Citation></Reference><Reference><Citation>Latvala J, von Hertzen L, Lindholm H, Haahtela T. Trends in prevalence of asthma and allergy in Finnish young men: nationwide study, 1966‐2003. BMJ. 2005;330(7501):1186‐1187.</Citation></Reference><Reference><Citation>Savouré M, Bousquet J, Jaakkola JJ, Jaakkola MS, Jacquemin B, Nadif R. Worldwide prevalence of rhinitis in adults: a review of definitions and temporal evolution. Clin Transl Allergy. 2022;12(3):e12130.</Citation></Reference><Reference><Citation>Nur Husna SM, Tan H‐TT, Md Shukri N, Mohd Ashari NS, Wong KK. Nasal epithelial barrier integrity and tight junctions disruption in allergic rhinitis: overview and pathogenic insights. Front Immunol. 2021;12:663626.</Citation></Reference><Reference><Citation>Steelant B, Farré R, Wawrzyniak P, et al. Impaired barrier function in patients with house dust mite–induced allergic rhinitis is accompanied by decreased occludin and zonula occludens‐1 expression. J Allergy Clin Immunol. 2016;137(4):1043‐1053.e5.</Citation></Reference><Reference><Citation>Lanza M, Casili G, Filippone A, et al. Evaluating the protective properties of a xyloglucan‐based nasal spray in a mouse model of allergic rhinitis. Int J Mol Sci. 2021;22(19):10472.</Citation></Reference><Reference><Citation>Sugita K, Soyka MB, Wawrzyniak P, et al. Outside‐in hypothesis revisited: the role of microbial, epithelial, and immune interactions. Ann Allergy Asthma Immunol. 2020;125(5):517‐527.</Citation></Reference><Reference><Citation>Azevedo AC, Hilário S, Gonçalves MF. Microbiome in nasal mucosa of children and adolescents with allergic rhinitis: a systematic review. Children. 2023;10(2):226.</Citation></Reference><Reference><Citation>Kim HJ, Kim J‐H, Han S‐A, Kim W. Compositional alterations of the nasal microbiome and Staphylococcus aureus–characterized Dysbiosis in the nasal mucosa of patients with allergic rhinitis. Clin Exp Otorhinolaryngol. 2022;15(4):335‐345.</Citation></Reference><Reference><Citation>Miao P, Jiang Y, Jian Y, et al. Exacerbation of allergic rhinitis by the commensal bacterium Streptococcus salivarius. Nat Microbiol. 2023;8:1‐13.</Citation></Reference><Reference><Citation>Sedaghat AR. Chronic rhinosinusitis. Am Fam Physician. 2017;96(8):500‐506.</Citation></Reference><Reference><Citation>Wise SK, Damask C, Roland LT, et al. International consensus statement on allergy and rhinology: allergic rhinitis – 2023. Int Forum Allergy Rhinol. 2023;13(4):293‐859.</Citation></Reference><Reference><Citation>Damm M, Quante G, Jungehuelsing M, Stennert E. Impact of functional endoscopic sinus surgery on symptoms and quality of life in chronic rhinosinusitis. Laryngoscope. 2002;112(2):310‐315.</Citation></Reference><Reference><Citation>Kaliner MA, Osguthorpe JD, Fireman P, et al. Sinusitis: bench to bedside: current findings, future directions. J Allergy Clin Immunol. 1997;99(6):S829‐S847.</Citation></Reference><Reference><Citation>Huang Z‐Q, Ye J, Liu J, et al. Predictive significance of Claudin‐3 for epithelial barrier dysfunction in chronic rhinosinusitis with nasal polyps. Allergy, Asthma Immunol Res. 2023;15(4):512.</Citation></Reference><Reference><Citation>Van Bruaene N, Pérez‐Novo CA, Basinski TM, et al. T‐cell regulation in chronic paranasal sinus disease. J Allergy Clin Immunol. 2008;121(6):1435‐1441.e1.</Citation></Reference><Reference><Citation>Van Zele T, Claeys S, Gevaert P, et al. Differentiation of chronic sinus diseases by measurement of inflammatory mediators. Allergy. 2006;61(11):1280‐1289.</Citation></Reference><Reference><Citation>Oka A, Kanai K, Higaki T, et al. Macroarray expression analysis of cytokines and prostaglandin metabolism–related genes in chronic rhinosinusitis. J Allergy Clin Immunol. 2023;2(3):100123.</Citation></Reference><Reference><Citation>Cho D‐Y, Hunter RC, Ramakrishnan VR. The microbiome and chronic rhinosinusitis. Immunol Allergy Clin. 2020;40(2):251‐263.</Citation></Reference><Reference><Citation>Hoggard M, Biswas K, Zoing M, Wagner Mackenzie B, Taylor MW, Douglas RG. Evidence of microbiota dysbiosis in chronic rhinosinusitis. Int Forum Allergy Rhinol. 2017;7(3):230‐239.</Citation></Reference><Reference><Citation>Wagner Mackenzie B, Waite DW, Hoggard M, Douglas RG, Taylor MW, Biswas K. Bacterial community collapse: a meta‐analysis of the sinonasal microbiota in chronic rhinosinusitis. Environ Microbiol. 2017;19(1):381‐392.</Citation></Reference><Reference><Citation>Ivanchenko O, Karpishchenko S, Kozlov R, et al. The microbiome of the maxillary sinus and middle nasal meatus in chronic rhinosinusitis. Rhinology. 2016;54(1):68‐74.</Citation></Reference><Reference><Citation>Senior RM, Anthonisen NR. Chronic obstructive pulmonary disease (COPD). Am J Respir Crit Care Med. 1998;157(4):S139‐S147.</Citation></Reference><Reference><Citation>Singh D, Agusti A, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: the GOLD science committee report 2019. Eur Respir J. 2019;53(5):1900164.</Citation></Reference><Reference><Citation>Lareau SC, Fahy B, Meek P, Wang A. Chronic obstructive pulmonary disease (COPD). Am J Respir Crit Care Med. 2019;199(1):P1‐P2.</Citation></Reference><Reference><Citation>Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380(9859):2095‐2128.</Citation></Reference><Reference><Citation>Guo P, Yokoyama K, Suenaga M, Kida H. Mortality and life expectancy of Yokkaichi asthma patients, Japan: late effects of air pollution in 1960–70s. Environ Health. 2008;7(1):1‐10.</Citation></Reference><Reference><Citation>Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC. Chronic obstructive pulmonary disease surveillance‐United States, 1971–2000. Respir Care. 2002;47:1184‐1199.</Citation></Reference><Reference><Citation>van den Berge M, Steiling K, Timens W, et al. Airway gene expression in COPD is dynamic with inhaled corticosteroid treatment and reflects biological pathways associated with disease activity. Thorax. 2014;69(1):14‐23.</Citation></Reference><Reference><Citation>Nishida K, Brune KA, Putcha N, et al. Cigarette smoke disrupts monolayer integrity by altering epithelial cell‐cell adhesion and cortical tension. Am J Phys Lung Cell Mol Phys. 2017;313(3):L581‐L591.</Citation></Reference><Reference><Citation>Heijink IH, Noordhoek JA, Timens W, van Oosterhout AJ, Postma DS. Abnormalities in airway epithelial junction formation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2014;189(11):1439‐1442.</Citation></Reference><Reference><Citation>Kolsum U, Damera G, Pham T‐H, et al. Pulmonary inflammation in patients with chronic obstructive pulmonary disease with higher blood eosinophil counts. J Allergy Clin Immunol. 2017;140(4):1181‐1184.e7.</Citation></Reference><Reference><Citation>Faner R, Sobradillo P, Noguera A, et al. The inflammasome pathway in stable COPD and acute exacerbations. ERJ Open Res. 2016;2(3):00002‐2016.</Citation></Reference><Reference><Citation>Zhang L, Cheng Z, Liu W, Wu K. Expression of interleukin (IL)‐10, IL‐17A and IL‐22 in serum and sputum of stable chronic obstructive pulmonary disease patients. COPD: J Chron Obstruct Pulmon Dis. 2013;10(4):459‐465.</Citation></Reference><Reference><Citation>Wang Z, Singh R, Miller BE, et al. Sputum microbiome temporal variability and dysbiosis in chronic obstructive pulmonary disease exacerbations: an analysis of the COPDMAP study. Thorax. 2018;73(4):331‐338.</Citation></Reference><Reference><Citation>Lederer DJ, Martinez FJ. Idiopathic pulmonary fibrosis. New Engl J Med. 2018;378(19):1811‐1823.</Citation></Reference><Reference><Citation>Cordier J‐F, Cottin V. Neglected evidence in idiopathic pulmonary fibrosis: from history to earlier diagnosis. Eur Respir J. 2013;42(4):916‐923.</Citation></Reference><Reference><Citation>Navaratnam V, Fleming K, West J, et al. The rising incidence of idiopathic pulmonary fibrosis in the UK. Thorax. 2011;66(6):462‐467.</Citation></Reference><Reference><Citation>Richeldi L, Collard HR, Jones MG. Idiopathic pulmonary fibrosis. Lancet. 2017;389(10082):1941‐1952.</Citation></Reference><Reference><Citation>Zou J, Li Y, Yu J, et al. Idiopathic pulmonary fibrosis is associated with tight junction protein alterations. Biochimica et Biophysica Acta (BBA)‐Biomembranes. 2020;1862(5):183205.</Citation></Reference><Reference><Citation>Kodera Y, Kohno T, Konno T, et al. HMGB1 enhances epithelial permeability via p63/TGF‐β signaling in lung and terminal bronchial epithelial cells. Tissue Barriers. 2020;8(4):1805997.</Citation></Reference><Reference><Citation>O'Dwyer DN, Ashley SL, Gurczynski SJ, et al. Lung microbiota contribute to pulmonary inflammation and disease progression in pulmonary fibrosis. Am J Respir Crit Care Med. 2019;199(9):1127‐1138.</Citation></Reference><Reference><Citation>Molyneaux PL, Cox MJ, Willis‐Owen SA, et al. The role of bacteria in the pathogenesis and progression of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2014;190(8):906‐913.</Citation></Reference><Reference><Citation>Antar SA, Saleh MA, Al‐Karmalawy AA. Investigating the possible mechanisms of pirfenidone to be targeted as a promising anti‐inflammatory, anti‐fibrotic, anti‐oxidant, anti‐apoptotic, anti‐tumor, and/or anti‐SARS‐CoV‐2. Life Sci. 2022;309:121048.</Citation></Reference><Reference><Citation>O'Shea KM, Aceves SS, Dellon ES, et al. Pathophysiology of eosinophilic esophagitis. Gastroenterology. 2018;154(2):333‐345.</Citation></Reference><Reference><Citation>Dobbins JW, Sheahan DG, Behar J. Eosinophilic gastroenteritis with esophageal involvement. Gastroenterology. 1977;72(6):1312‐1316.</Citation></Reference><Reference><Citation>Attwood SE, Smyrk TC, Demeester TR, Jones JB. Esophageal eosinophilia with dysphagia: a distinct clinicopathologic syndrome. Dig Dis Sci. 1993;38:109‐116.</Citation></Reference><Reference><Citation>Hommeida S, Grothe R, Hafed Y, et al. Assessing the incidence trend and characteristics of eosinophilic esophagitis in children in Olmsted County, Minnesota. Dis Esophagus. 2018;31(12):doy062.</Citation></Reference><Reference><Citation>Arias A, Pérez‐Martínez I, Tenías J, Lucendo A. Systematic review with meta‐analysis: the incidence and prevalence of eosinophilic oesophagitis in children and adults in population‐based studies. Aliment Pharmacol Ther. 2016;43(1):3‐15.</Citation></Reference><Reference><Citation>Hirano I, Dellon ES. Eosinophilic Esophagitis. 6th ed. Wiley; 2021.</Citation></Reference><Reference><Citation>Kliewer KL, Gonsalves N, Dellon ES, et al. One‐food versus six‐food elimination diet therapy for the treatment of eosinophilic oesophagitis: a multicentre, randomised, open‐label trial. Lancet Gastroenterol Hepatol. 2023;8(5):408‐421.</Citation></Reference><Reference><Citation>Wechsler JB, Schwartz S, Arva NC, et al. A single‐food milk elimination diet is effective for treatment of eosinophilic esophagitis in children. Clin Gastroenterol Hepatol. 2022;20(8):1748‐1756 e1711.</Citation></Reference><Reference><Citation>Katzka DA, Ravi K, Geno DM, et al. Endoscopic mucosal impedance measurements correlate with eosinophilia and dilation of intercellular spaces in patients with eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2015;13(7):1242‐1248.e1.</Citation></Reference><Reference><Citation>Simon D, Page B, Vogel M, et al. Evidence of an abnormal epithelial barrier in active, untreated and corticosteroid‐treated eosinophilic esophagitis. Allergy. 2018;73(1):239‐247.</Citation></Reference><Reference><Citation>Furuta GT, Katzka DA. Eosinophilic esophagitis. New Engl J Med. 2015;373(17):1640‐1648.</Citation></Reference><Reference><Citation>Massimino L, Barchi A, Mandarino FV, et al. A multi‐omic analysis reveals the esophageal dysbiosis as the predominant trait of eosinophilic esophagitis. J Transl Med. 2023;21(1):46.</Citation></Reference><Reference><Citation>Mennini M, Tambucci R, Riccardi C, et al. Eosinophilic esophagitis and microbiota: state of the art. Front Immunol. 2021;12:595762.</Citation></Reference><Reference><Citation>Kellerman R, Kintanar T. Gastroesophageal reflux disease. Primary Care: Clin Office Pract. 2017;44(4):561‐573.</Citation></Reference><Reference><Citation>El‐Serag H, Sonnenberg A. Opposing time trends of peptic ulcer and reflux disease. Gut. 1998;43(3):327‐333.</Citation></Reference><Reference><Citation>Hampel H, Abraham NS, El‐Serag HB. Meta‐analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med. 2005;143(3):199‐211.</Citation></Reference><Reference><Citation>Björkman E, Casselbrant A, Lundberg S, Fändriks L. In vitro assessment of epithelial electrical resistance in human esophageal and jejunal mucosae and in Caco‐2 cell layers. Scand J Gastroenterol. 2012;47(11):1321‐1333.</Citation></Reference><Reference><Citation>Orlando R, Powell D, Carney CN. Pathophysiology of acute acid injury in rabbit esophageal epithelium. J Clin Invest. 1981;68(1):286‐293.</Citation></Reference><Reference><Citation>Björkman EVC, Edebo A, Oltean M, Casselbrant A. Esophageal barrier function and tight junction expression in healthy subjects and patients with gastroesophageal reflux disease: functionality of esophageal mucosa exposed to bile salt and trypsin in vitro. Scand J Gastroenterol. 2013;48(10):1118‐1126.</Citation></Reference><Reference><Citation>Souza RF, Huo X, Mittal V, et al. Gastroesophageal reflux might cause esophagitis through a cytokine‐mediated mechanism rather than caustic acid injury. Gastroenterology. 2009;137(5):1776‐1784.</Citation></Reference><Reference><Citation>Blackett K, Siddhi S, Cleary S, et al. Oesophageal bacterial biofilm changes in gastro‐oesophageal reflux disease, Barrett's and oesophageal carcinoma: association or causality? Aliment Pharmacol Ther. 2013;37(11):1084‐1092.</Citation></Reference><Reference><Citation>Profumo RJ. Barrett's esophagus. J Insur Med. 2002;34(1):70‐73.</Citation></Reference><Reference><Citation>Kiesslich R, Gossner L, Goetz M, et al. In vivo histology of Barrett's esophagus and associated neoplasia by confocal laser endomicroscopy. Clin Gastroenterol Hepatol. 2006;4(8):979‐987.</Citation></Reference><Reference><Citation>Conio M, Cameron A, Romero Y, et al. Secular trends in the epidemiology and outcome of Barrett's oesophagus in Olmsted County, Minnesota. Gut. 2001;48(3):304‐309.</Citation></Reference><Reference><Citation>Gill RS, Singh R. Endoscopic imaging in Barrett's esophagus: current practice and future applications. Ann Gastroenterol. 2012;25(2):89.</Citation></Reference><Reference><Citation>Ghatwary N, Ahmed A, Ye X, Jalab H. Automatic grade classification of Barretts esophagus through feature enhancement. Paper presented at: Medical Imaging 2017: Computer‐Aided Diagnosis. 2017.</Citation></Reference><Reference><Citation>Mullin J, Valenzano M, Trembeth S, et al. Transepithelial leak in Barrett's esophagus. Dig Dis Sci. 2006;51(12):2326‐2336.</Citation></Reference><Reference><Citation>Farrell C, Morgan M, Tully O, et al. Transepithelial leak in Barrett's esophagus patients: the role of proton pump inhibitors. World J Gastroenterol: WJG. 2012;18(22):2793.</Citation></Reference><Reference><Citation>Yang L, Lu X, Nossa CW, Francois F, Peek RM, Pei Z. Inflammation and intestinal metaplasia of the distal esophagus are associated with alterations in the microbiome. Gastroenterology. 2009;137(2):588‐597.</Citation></Reference><Reference><Citation>Yang L, Francois F, Pei Z. Molecular pathways: pathogenesis and clinical implications of microbiome alteration in esophagitis and Barrett esophagus. Clin Cancer Res. 2012;18(8):2138‐2144.</Citation></Reference><Reference><Citation>Morris CD, Armstrong GR, Bigley G, Green H, Attwood SE. Cyclooxygenase‐2 expression in the Barrett's metaplasia–dysplasia–adenocarcinoma sequence. Am J Gastroenterol. 2001;96(4):990‐996.</Citation></Reference><Reference><Citation>Sicherer SH, Sampson HA. Food allergy: a review and update on epidemiology, pathogenesis, diagnosis, prevention, and management. J Allergy Clin Immunol. 2018;141(1):41‐58.</Citation></Reference><Reference><Citation>Sampath V, Abrams EM, Adlou B, et al. Food allergy across the globe. J Allergy Clin Immunol. 2021;148(6):1347‐1364.</Citation></Reference><Reference><Citation>Turner PJ, Gowland MH, Sharma V, et al. Increase in anaphylaxis‐related hospitalizations but no increase in fatalities: an analysis of United Kingdom national anaphylaxis data, 1992–2012. J Allergy Clin Immunol. 2015;135(4):956‐963.e1.</Citation></Reference><Reference><Citation>Mullins RJ, Dear KB, Tang ML. Time trends in Australian hospital anaphylaxis admissions in 1998–1999 to 2011–2012. J Allergy Clin Immunol. 2015;136(2):367‐375.</Citation></Reference><Reference><Citation>Lockhart A, Reed A, Rezende de Castro T, Herman C, Campos Canesso MC, Mucida D. Dietary protein shapes the profile and repertoire of intestinal CD4+ T cells. J Exp Med. 2023;220(8):e20221816.</Citation></Reference><Reference><Citation>Hong SW, Krueger PD, Osum KC, et al. Immune tolerance of food is mediated by layers of CD4(+) T cell dysfunction. Nature. 2022;607(7920):762‐768.</Citation></Reference><Reference><Citation>Fukaya T, Uto T, Mitoma S, et al. Gut dysbiosis promotes the breakdown of oral tolerance mediated through dysfunction of mucosal dendritic cells. Cell Rep. 2023;42(5):112431.</Citation></Reference><Reference><Citation>Rath T, Dieterich W, Kätscher‐Murad C, Neurath MF, Zopf Y. Cross‐sectional imaging of intestinal barrier dysfunction by confocal laser endomicroscopy can identify patients with food allergy in vivo with high sensitivity. Sci Rep. 2021;11(1):1‐9.</Citation></Reference><Reference><Citation>Ungar B, da Rosa JC, Shemer A, et al. Patch testing of food allergens promotes Th17 and Th2 responses with increased IL‐33: a pilot study. Exp Dermatol. 2017;26(3):272‐275.</Citation></Reference><Reference><Citation>Ukleja‐Sokołowska N, Żbikowska‐Gotz M, Lis K, Adamczak R, Bartuzi Z. Assessment of TSLP, IL 25 and IL 33 in patients with shrimp allergy. Allergy, Asthma Clin Immunol. 2021;17(1):1‐11.</Citation></Reference><Reference><Citation>Khodoun MV, Tomar S, Tocker JE, Wang YH, Finkelman FD. Prevention of food allergy development and suppression of established food allergy by neutralization of thymic stromal lymphopoietin, IL‐25, and IL‐33. J Allergy Clin Immunol. 2018;141(1):171‐179.e1.</Citation></Reference><Reference><Citation>Kourosh A, Luna RA, Balderas M, et al. Fecal microbiome signatures are different in food‐allergic children compared to siblings and healthy children. Pediatr Allergy Immunol. 2018;29(5):545‐554.</Citation></Reference><Reference><Citation>Rivas MN, Burton OT, Wise P, et al. A microbiota signature associated with experimental food allergy promotes allergic sensitization and anaphylaxis. J Allergy Clin Immunol. 2013;131(1):201‐212.</Citation></Reference><Reference><Citation>Korpela K, Hurley S, Ford SA, et al. Association between gut microbiota development and allergy in infants born during pandemic‐related social distancing restrictions. Allergy. 2024;79:1938‐1951.</Citation></Reference><Reference><Citation>Sairenji T, Collins KL, Evans DV. An update on inflammatory bowel disease. Prim Care. 2017;44(4):673‐692.</Citation></Reference><Reference><Citation>Agrawal M, Christensen HS, Bøgsted M, Colombel J‐F, Jess T, Allin KH. The rising burden of inflammatory bowel disease in Denmark over two decades: a nationwide cohort study. Gastroenterology. 2022;163(6):1547‐1554.e5.</Citation></Reference><Reference><Citation>Kaplan GG. The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol. 2015;12(12):720‐727.</Citation></Reference><Reference><Citation>Kaplan GG, Ng SC. Understanding and preventing the global increase of inflammatory bowel disease. Gastroenterology. 2017;152(2):313‐321.e2.</Citation></Reference><Reference><Citation>Martini E, Krug SM, Siegmund B, Neurath MF, Becker C. Mend your fences: the epithelial barrier and its relationship with mucosal immunity in inflammatory bowel disease. Cell Mol Gastroenterol Hepatol. 2017;4(1):33‐46.</Citation></Reference><Reference><Citation>Zeissig S, Bürgel N, Günzel D, et al. Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn's disease. Gut. 2007;56(1):61‐72.</Citation></Reference><Reference><Citation>Oshima T, Miwa H, Joh T. Changes in the expression of claudins in active ulcerative colitis. J Gastroenterol Hepatol. 2008;23:S146‐S150.</Citation></Reference><Reference><Citation>Madsen KL, Malfair D, Gray D, Doyle JS, Jewell LD, Fedorak RN. Interleukin‐10 gene‐deficient mice develop a primary intestinal permeability defect in response to enteric microflora. Inflamm Bowel Dis. 1999;5(4):262‐270.</Citation></Reference><Reference><Citation>Neut C, Bulois P, Desreumaux P, et al. Changes in the bacterial flora of the neoterminal ileum after ileocolonic resection for Crohn's disease. Am J Gastroenterol. 2002;97(4):939‐946.</Citation></Reference><Reference><Citation>Ott S, Musfeldt M, Wenderoth D, et al. Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut. 2004;53(5):685‐693.</Citation></Reference><Reference><Citation>Halfvarson J, Brislawn CJ, Lamendella R, et al. Dynamics of the human gut microbiome in inflammatory bowel disease. Nat Microbiol. 2017;2(5):1‐7.</Citation></Reference><Reference><Citation>Fasano A, Catassi C. Celiac disease. N Engl J Med. 2012;367(25):2419‐2426.</Citation></Reference><Reference><Citation>Grode L, Bech BH, Jensen TM, et al. Prevalence, incidence, and autoimmune comorbidities of celiac disease: a nation‐wide, population‐based study in Denmark from 1977 to 2016. Eur J Gastroenterol Hepatol. 2018;30(1):83‐91.</Citation></Reference><Reference><Citation>Catassi C, Kryszak D, Bhatti B, et al. Natural history of celiac disease autoimmunity in a USA cohort followed since 1974. Ann Med. 2010;42(7):530‐538.</Citation></Reference><Reference><Citation>Rubio‐Tapia A, Ludvigsson JF, Brantner TL, Murray JA, Everhart JE. The prevalence of celiac disease in the United States. Official J Am College Gastroenterol. 2012;107(10):1538‐1544.</Citation></Reference><Reference><Citation>Schumann M, Siegmund B, Schulzke JD, Fromm M. Celiac disease: role of the epithelial barrier. Cell Mol Gastroenterol Hepatol. 2017;3(2):150‐162.</Citation></Reference><Reference><Citation>Cukrowska B, Sowińska A, Bierła JB, Czarnowska E, Rybak A, Grzybowska‐Chlebowczyk U. Intestinal epithelium, intraepithelial lymphocytes and the gut microbiota‐Key players in the pathogenesis of celiac disease. World J Gastroenterol. 2017;23(42):7505.</Citation></Reference><Reference><Citation>Schumann M, Günzel D, Buergel N, et al. Cell polarity‐determining proteins par‐3 and PP‐1 are involved in epithelial tight junction defects in coeliac disease. Gut. 2012;61(2):220‐228.</Citation></Reference><Reference><Citation>Pozo‐Rubio T, Olivares M, Nova E, et al. Immune development and intestinal microbiota in celiac disease. Clin Dev Immunol. 2012;2012:654143.</Citation></Reference><Reference><Citation>Girbovan A, Sur G, Samasca G, Lupan I. Dysbiosis a risk factor for celiac disease. Med Microbiol Immunol. 2017;206:83‐91.</Citation></Reference><Reference><Citation>Black CJ, Ford AC. Global burden of irritable bowel syndrome: trends, predictions and risk factors. Nat Rev Gastroenterol Hepatol. 2020;17(8):473‐486.</Citation></Reference><Reference><Citation>Gwee KA, Lu CL, Ghoshal UC. Epidemiology of irritable bowel syndrome in Asia: something old, something new, something borrowed. J Gastroenterol Hepatol. 2009;24(10):1601‐1607.</Citation></Reference><Reference><Citation>Gwee KA. Irritable bowel syndrome in developing countries–a disorder of civilization or colonization? Neurogastroenterol Motil. 2005;17(3):317‐324.</Citation></Reference><Reference><Citation>Zhou Q, Zhang B, Verne GN. Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome. Pain. 2009;146(1–2):41‐46.</Citation></Reference><Reference><Citation>Martínez C, Vicario M, Ramos L, et al. The jejunum of diarrhea‐predominant irritable bowel syndrome shows molecular alterations in the tight junction signaling pathway that are associated with mucosal pathobiology and clinical manifestations. Official J Am College Gastroenterol. 2012;107(5):736‐746.</Citation></Reference><Reference><Citation>Fritscher‐Ravens A, Schuppan D, Ellrichmann M, et al. Confocal endomicroscopy shows food‐associated changes in the intestinal mucosa of patients with irritable bowel syndrome. Gastroenterology. 2014;147(5):1012‐1020.e4.</Citation></Reference><Reference><Citation>Fritscher‐Ravens A, Pflaum T, Mosinger M, et al. Many patients with irritable bowel syndrome have atypical food allergies not associated with immunoglobulin E. Gastroenterology. 2019;157(1):109‐118 e105.</Citation></Reference><Reference><Citation>Macsharry J, O'Mahony L, Fanning A, et al. Mucosal cytokine imbalance in irritable bowel syndrome. Scand J Gastroenterol. 2008;43(12):1467‐1476.</Citation></Reference><Reference><Citation>Aerssens J, Camilleri M, Talloen W, et al. Alterations in mucosal immunity identified in the colon of patients with irritable bowel syndrome. Clin Gastroenterol Hepatol. 2008;6(2):194‐205.</Citation></Reference><Reference><Citation>Tursi A, Scarpignato C, Strate LL, et al. Colonic diverticular disease. Nat Rev Dis Primers. 2020;6(1):1‐23.</Citation></Reference><Reference><Citation>Kang J, Hoare J, Tinto A, et al. Diverticular disease of the colon—on the rise: a study of hospital admissions in England between 1989/1990 and 1999/2000. Aliment Pharmacol Ther. 2003;17(9):1189‐1195.</Citation></Reference><Reference><Citation>Yamamichi N, Shimamoto T, Takahashi Y, et al. Trend and risk factors of diverticulosis in Japan: age, gender, and lifestyle/metabolic‐related factors may cooperatively affect on the colorectal diverticula formation. PLoS One. 2015;10(4):e0123688.</Citation></Reference><Reference><Citation>Crowe FL, Appleby PN, Allen NE, Key TJ. Diet and risk of diverticular disease in Oxford cohort of European prospective investigation into cancer and nutrition (EPIC): prospective study of British vegetarians and non‐vegetarians. BMJ. 2011;343:d4131.</Citation></Reference><Reference><Citation>Cao Y, Strate LL, Keeley BR, et al. Meat intake and risk of diverticulitis among men. Gut. 2018;67(3):466‐472.</Citation></Reference><Reference><Citation>Hjern F, Wolk A, Håkansson N. Smoking and the risk of diverticular disease in women. J Br Surg. 2011;98(7):997‐1002.</Citation></Reference><Reference><Citation>Ma W, Jovani M, Liu P‐H, et al. Association between obesity and weight change and risk of diverticulitis in women. Gastroenterology. 2018;155(1):58‐66.e4.</Citation></Reference><Reference><Citation>Strate LL, Liu YL, Aldoori WH, Giovannucci EL. Physical activity decreases diverticular complications. Am J Gastroenterol. 2009;104(5):1221.</Citation></Reference><Reference><Citation>Ma W, Jovani M, Nguyen LH, et al. Association between inflammatory diets, circulating markers of inflammation, and risk of diverticulitis. Clin Gastroenterol Hepatol. 2020;18(10):2279‐2286.e3.</Citation></Reference><Reference><Citation>Altomare A, Gori M, Cocca S, et al. Impaired colonic contractility and intestinal permeability in symptomatic uncomplicated diverticular disease. J Neurogastroenterol Motility. 2021;27(2):292.</Citation></Reference><Reference><Citation>Barbara G, Scaioli E, Barbaro MR, et al. Gut microbiota, metabolome and immune signatures in patients with uncomplicated diverticular disease. Gut. 2017;66(7):1252‐1261.</Citation></Reference><Reference><Citation>Chiarotti F, Venerosi A. Epidemiology of autism spectrum disorders: a review of worldwide prevalence estimates since 2014. Brain Sci. 2020;10(5):274.</Citation></Reference><Reference><Citation>Savica R, Grossardt BR, Bower JH, Ahlskog JE, Rocca WA. Time trends in the incidence of Parkinson disease. JAMA Neurol. 2016;73(8):981‐989.</Citation></Reference><Reference><Citation>Hidaka BH. Depression as a disease of modernity: explanations for increasing prevalence. J Affect Disord. 2012;140(3):205‐214.</Citation></Reference><Reference><Citation>Cornutiu G. The epidemiological scale of Alzheimer's disease. J Clin Med Res. 2015;7(9):657.</Citation></Reference><Reference><Citation>Homolak J, Perhoc AB, Knezovic A, et al. Disbalance of the intestinal epithelial cell turnover and apoptosis in a rat model of sporadic Alzheimer's disease. bioRxiv. 2004. doi:10.1101/2021.04.22.440947</Citation></Reference><Reference><Citation>Liao W, Wei J, Liu C, et al. Magnesium‐L‐threonate treats Alzheimer's disease by modulating the microbiota‐gut‐brain axis. Neural Regen Res. 2024;19(10):2281‐2289.</Citation></Reference><Reference><Citation>Asghari K, Niknam Z, Mohammadpour‐Asl S, Chodari L. Cellular junction dynamics and Alzheimer's disease: a comprehensive review. Mol Biol Rep. 2024;51(1):273.</Citation></Reference><Reference><Citation>Vogt NM, Kerby RL, Dill‐McFarland KA, et al. Gut microbiome alterations in Alzheimer's disease. Sci Rep. 2017;7(1):13537.</Citation></Reference><Reference><Citation>Pellegrini C, Antonioli L, Colucci R, Blandizzi C, Fornai M. Interplay among gut microbiota, intestinal mucosal barrier and enteric neuro‐immune system: a common path to neurodegenerative diseases? Acta Neuropathol. 2018;136:345‐361.</Citation></Reference><Reference><Citation>Bloem BR, Okun MS, Klein C. Parkinson's disease. Lancet. 2021;397(10291):2284‐2303.</Citation></Reference><Reference><Citation>Jankovic J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008;79(4):368‐376.</Citation></Reference><Reference><Citation>Ou Z, Pan J, Tang S, et al. Global trends in the incidence, prevalence, and years lived with disability of Parkinson's disease in 204 countries/territories from 1990 to 2019. Front Public Health. 2021;9:776847.</Citation></Reference><Reference><Citation>Derkinderen P, Rouaud T, Lebouvier T, Des Varannes SB, Neunlist M, De Giorgio R. Parkinson disease: the enteric nervous system spills its guts. Neurology. 2011;77(19):1761‐1767.</Citation></Reference><Reference><Citation>Forsyth CB, Shannon KM, Kordower JH, et al. Increased intestinal permeability correlates with sigmoid mucosa alpha‐synuclein staining and endotoxin exposure markers in early Parkinson's disease. PLoS One. 2011;6(12):e28032.</Citation></Reference><Reference><Citation>van IJzendoorn SC, Derkinderen P. The intestinal barrier in Parkinson's disease: current state of knowledge. J Parkinsons Dis. 2019;9(s2):S323‐S329.</Citation></Reference><Reference><Citation>Clairembault T, Leclair‐Visonneau L, Coron E, et al. Structural alterations of the intestinal epithelial barrier in Parkinson's disease. Acta Neuropathol Commun. 2015;3:1‐9.</Citation></Reference><Reference><Citation>World Health Organization. Autism Spectrum Disorders. World Health Organization. Regional Office for the Eastern Mediterranean; 2019.</Citation></Reference><Reference><Citation>Idring S, Lundberg M, Sturm H, et al. Changes in prevalence of autism spectrum disorders in 2001–2011: findings from the Stockholm youth cohort. J Autism Dev Disord. 2015;45:1766‐1773.</Citation></Reference><Reference><Citation>Raz R, Roberts AL, Lyall K, et al. Autism spectrum disorder and particulate matter air pollution before, during, and after pregnancy: a nested case–control analysis within the Nurses' health study II cohort. Environ Health Perspect. 2015;123(3):264‐270.</Citation></Reference><Reference><Citation>Shelton JF, Geraghty EM, Tancredi DJ, et al. Neurodevelopmental disorders and prenatal residential proximity to agricultural pesticides: the CHARGE study. Environ Health Perspect. 2014;122(10):1103‐1109.</Citation></Reference><Reference><Citation>Atladóttir HÓ, Henriksen TB, Schendel DE, Parner ET. Autism after infection, febrile episodes, and antibiotic use during pregnancy: an exploratory study. Pediatrics. 2012;130(6):e1447‐e1454.</Citation></Reference><Reference><Citation>Zimmerman AW, Jyonouchi H, Comi AM, et al. Cerebrospinal fluid and serum markers of inflammation in autism. Pediatr Neurol. 2005;33(3):195‐201.</Citation></Reference><Reference><Citation>Pardo CA, Vargas DL, Zimmerman AW. Immunity, neuroglia and neuroinflammation in autism. Int Rev Psychiatry. 2005;17(6):485‐495.</Citation></Reference><Reference><Citation>Estes ML, McAllister AK. Immune mediators in the brain and peripheral tissues in autism spectrum disorder. Nat Rev Neurosci. 2015;16(8):469‐486.</Citation></Reference><Reference><Citation>D'Eufemia P, Celli M, Finocchiaro R, et al. Abnormal intestinal permeability in children with autism. Acta Paediatr. 1996;85(9):1076‐1079.</Citation></Reference><Reference><Citation>De Magistris L, Familiari V, Pascotto A, et al. Alterations of the intestinal barrier in patients with autism spectrum disorders and in their first‐degree relatives. J Pediatr Gastroenterol Nutr. 2010;51(4):418‐424.</Citation></Reference><Reference><Citation>Fiorentino M, Sapone A, Senger S, et al. Blood–brain barrier and intestinal epithelial barrier alterations in autism spectrum disorders. Mol Autism. 2016;7(1):1‐17.</Citation></Reference><Reference><Citation>Hughes HK, Rose D, Ashwood P. The gut microbiota and dysbiosis in autism spectrum disorders. Curr Neurol Neurosci Rep. 2018;18:1‐15.</Citation></Reference><Reference><Citation>Weinberger AH, Gbedemah M, Martinez AM, Nash D, Galea S, Goodwin RD. Trends in depression prevalence in the USA from 2005 to 2015: widening disparities in vulnerable groups. Psychol Med. 2018;48(8):1308‐1315.</Citation></Reference><Reference><Citation>Kim GE, Jo M‐W, Shin Y‐W. Increased prevalence of depression in South Korea from 2002 to 2013. Sci Rep. 2020;10(1):16979.</Citation></Reference><Reference><Citation>Trzeciak P, Herbet M. Role of the intestinal microbiome, intestinal barrier and psychobiotics in depression. Nutrients. 2021;13(3):927.</Citation></Reference><Reference><Citation>Doney E, Dion‐Albert L, Coulombe‐Rozon F, et al. Chronic stress exposure alters the gut barrier: sex‐specific effects on microbiota and jejunum tight junctions. Biol Psychiatry Global Open Sci. 2024;4(1):213‐228.</Citation></Reference><Reference><Citation>Kelly JR, Kennedy PJ, Cryan JF, Dinan TG, Clarke G, Hyland NP. Breaking down the barriers: the gut microbiome, intestinal permeability and stress‐related psychiatric disorders. Front Cell Neurosci. 2015;9:392.</Citation></Reference><Reference><Citation>Maes M, Kubera M, Leunis JC, Berk M. Increased IgA and IgM responses against gut commensals in chronic depression: further evidence for increased bacterial translocation or leaky gut. J Affect Disord. 2012;141(1):55‐62.</Citation></Reference><Reference><Citation>Boursin P, Paternotte S, Dercy B, Sabben C, Maïer B. Semantics, epidemiology and semiology of stroke. Soins. 2018;63(828):24‐27.</Citation></Reference><Reference><Citation>Higashida RT. What is stroke? From: the cerebrovascular imaging and interventions committee of the american heart association cardiovascular radiology council. 2003.</Citation></Reference><Reference><Citation>Béjot Y, Bailly H, Durier J, Giroud M. Epidemiology of stroke in Europe and trends for the 21st century. Presse Med. 2016;45(12):e391‐e398.</Citation></Reference><Reference><Citation>Ekker MS, Verhoeven JI, Vaartjes I, van Nieuwenhuizen KM, Klijn CJ, de Leeuw F‐E. Stroke incidence in young adults according to age, subtype, sex, and time trends. Neurology. 2019;92(21):e2444‐e2454.</Citation></Reference><Reference><Citation>Tsao CW, Aday AW, Almarzooq ZI, et al. Heart disease and stroke statistics—2022 update: a report from the American Heart Association. Circulation. 2022;145(8):e153‐e639.</Citation></Reference><Reference><Citation>Benakis C, Liesz A. The gut‐brain axis in ischemic stroke: its relevance in pathology and as a therapeutic target. Neurol Res Pract. 2022;4(1):57.</Citation></Reference><Reference><Citation>Yin J, Liao SX, He Y, et al. Dysbiosis of gut microbiota with reduced trimethylamine‐N‐oxide level in patients with large‐artery atherosclerotic stroke or transient ischemic attack. J Am Heart Assoc. 2015;4(11):e002699.</Citation></Reference><Reference><Citation>Crapser J, Ritzel R, Verma R, et al. Ischemic stroke induces gut permeability and enhances bacterial translocation leading to sepsis in aged mice. Aging (Albany NY). 2016;8(5):1049.</Citation></Reference><Reference><Citation>Pietrobon D, Moskowitz MA. Pathophysiology of migraine. Annu Rev Physiol. 2013;75:365‐391.</Citation></Reference><Reference><Citation>Centers for Disease Control (CDC). Prevalence of chronic migraine headaches–United States, 1980–1989. MMWR Morb Mortal Wkly Rep. 1991;40(20):331‐338.</Citation></Reference><Reference><Citation>Sillanpää M, Anttila P. Increasing prevalence of headache in 7‐year‐old schoolchildren. Headache. 1996;36(8):466‐470.</Citation></Reference><Reference><Citation>van Hemert S, Breedveld AC, Rovers JM, et al. Migraine associated with gastrointestinal disorders: review of the literature and clinical implications. Front Neurol. 2014;5:241.</Citation></Reference><Reference><Citation>Lau CI, Lin CC, Chen WH, Wang HC, Kao CH. Association between migraine and irritable bowel syndrome: a population‐based retrospective cohort study. Eur J Neurol. 2014;21(9):1198‐1204.</Citation></Reference><Reference><Citation>Dimitrova AK, Ungaro RC, Lebwohl B, et al. Prevalence of migraine in patients with celiac disease and inflammatory bowel disease. Headache. 2013;53(2):344‐355.</Citation></Reference><Reference><Citation>Scarpellini E, Ferraro D, Lauritano C, et al. Intestinal permeability in migraineurs. Dig Liver Dis. 2009;41:S143.</Citation></Reference><Reference><Citation>Kemper R, Meijler W, Korf J, Ter Horst G. Migraine and function of the immune system: a meta‐analysis of clinical literature published between 1966 and 1999. Cephalalgia. 2001;21(5):549‐557.</Citation></Reference><Reference><Citation>Chen J, Wang Q, Wang A, Lin Z. Structural and functional characterization of the gut microbiota in elderly women with migraine. Front Cell Infect Microbiol. 2020;9:470.</Citation></Reference><Reference><Citation>Tomer Y, Huber A. The etiology of autoimmune thyroid disease: a story of genes and environment. J Autoimmun. 2009;32(3–4):231‐239.</Citation></Reference><Reference><Citation>Weetman AP. Autoimmune thyroid disease: propagation and progression. Eur J Endocrinol. 2003;148(1):1‐9.</Citation></Reference><Reference><Citation>Prummel MF, Wiersinga WM. Smoking and risk of Graves' disease. JAMA. 1993;269(4):479‐482.</Citation></Reference><Reference><Citation>Berglund J, Christensen SB, Hallengren B. Total and age‐specific incidence of Graves' thyrotoxicosis, toxic nodular goitre and solitary toxic adenoma in Malmö 1970–74. J Intern Med. 1990;227(2):137‐141.</Citation></Reference><Reference><Citation>Berglund J, Ericsson UB, Hallengren B. Increased incidence of thyrotoxicosis in Malmö during the years 1988–1990 as compared to the years 1970–1974. J Intern Med. 1996;239(1):57‐62.</Citation></Reference><Reference><Citation>McLeod DS, Cooper DS. The incidence and prevalence of thyroid autoimmunity. Endocrine. 2012;42:252‐265.</Citation></Reference><Reference><Citation>Zaletel K, Gaberšček S, Pirnat E, Krhin B, Hojker S. Ten‐year follow‐up of thyroid epidemiology in Slovenia after increase in salt iodization. Croat Med J. 2011;52(5):615‐621.</Citation></Reference><Reference><Citation>Bargiel P, Szczuko M, Stachowska L, et al. Microbiome metabolites and thyroid dysfunction. J Clin Med. 2021;10(16):3609.</Citation></Reference><Reference><Citation>Zheng D, Liao H, Chen S, et al. Elevated levels of circulating biomarkers related to leaky gut syndrome and bacterial translocation are associated with graves' disease. Front Endocrinol. 2021;12:796212.</Citation></Reference><Reference><Citation>Sasso F, Carbonara O, Torella R, et al. Ultrastructural changes in enterocytes in subjects with Hashimoto's thyroiditis. Gut. 2004;53(12):1878‐1880.</Citation></Reference><Reference><Citation>Yan H‐x, An W‐c, Chen F, et al. Intestinal microbiota changes in Graves' disease: a prospective clinical study. Biosci Rep. 2020;40(9):BSR20191242.</Citation></Reference><Reference><Citation>Zhao F, Feng J, Li J, et al. Alterations of the gut microbiota in Hashimoto's thyroiditis patients. Thyroid. 2018;28(2):175‐186.</Citation></Reference><Reference><Citation>Cornejo‐Pareja I, Ruiz‐Limón P, Gómez‐Pérez AM, Molina‐Vega M, Moreno‐Indias I, Tinahones FJ. Differential microbial pattern description in subjects with autoimmune‐based thyroid diseases: a pilot study. J Personal Med. 2020;10(4):192.</Citation></Reference><Reference><Citation>Palazzo C, Nguyen C, Lefevre‐Colau M‐M, Rannou F, Poiraudeau S. Risk factors and burden of osteoarthritis. Ann Phys Rehabil Med. 2016;59(3):134‐138.</Citation></Reference><Reference><Citation>Zhang W, Doherty M. EULAR recommendations for knee and hip osteoarthritis: a critique of the methodology. Br J Sports Med. 2006;40(8):664‐669.</Citation></Reference><Reference><Citation>Wallace IJ, Worthington S, Felson DT, et al. Knee osteoarthritis has doubled in prevalence since the mid‐20th century. Proc Natl Acad Sci. 2017;114(35):9332‐9336.</Citation></Reference><Reference><Citation>Dagenais S, Garbedian S, Wai EK. Systematic review of the prevalence of radiographic primary hip osteoarthritis. Clin Orthop Relat Res. 2009;467(3):623‐637.</Citation></Reference><Reference><Citation>Favazzo LJ, Hendesi H, Villani DA, et al. The gut microbiome‐joint connection: implications in osteoarthritis. Curr Opin Rheumatol. 2020;32(1):92.</Citation></Reference><Reference><Citation>Ramires LC, Santos GS, Ramires RP, et al. The association between gut microbiota and osteoarthritis: does the disease begin in the gut? Int J Mol Sci. 2022;23(3):1494.</Citation></Reference><Reference><Citation>Huang Z, Stabler T, Pei F, Kraus VB. Both systemic and local lipopolysaccharide (LPS) burden are associated with knee OA severity and inflammation. Osteoarthr Cartil. 2016;24(10):1769‐1775.</Citation></Reference><Reference><Citation>Guss JD, Ziemian SN, Luna M, et al. The effects of metabolic syndrome, obesity, and the gut microbiome on load‐induced osteoarthritis. Osteoarthr Cartil. 2019;27(1):129‐139.</Citation></Reference><Reference><Citation>Herzog W, Collins KH, Paul HA, Reimer RA, Seerattan RA, Hart DA. Relationship between inflammation, the gut microbiota, and metabolic osteoarthritis development: studies in a rat model. Osteoarthr Cartil. 2016;23(11):1989.</Citation></Reference><Reference><Citation>Huang Z, Chen J, Li B, et al. Faecal microbiota transplantation from metabolically compromised human donors accelerates osteoarthritis in mice. Ann Rheum Dis. 2020;79(5):646‐656.</Citation></Reference><Reference><Citation>Schena FP, Nistor I. Epidemiology of IgA nephropathy: a global perspective. Semin Nephrol. 2018;38(5):435‐442.</Citation></Reference><Reference><Citation>McGrogan A, Franssen CF, de Vries CS. The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. Nephrol Dial Transplant. 2011;26(2):414‐430.</Citation></Reference><Reference><Citation>Kano T, Suzuki H, Makita Y, et al. Mucosal immune system dysregulation in the pathogenesis of IgA nephropathy. Biomedicine. 2022;10(12):3027.</Citation></Reference><Reference><Citation>Suzuki H, Kiryluk K, Novak J, et al. The pathophysiology of IgA nephropathy. J Am Soc Nephrol. 2011;22(10):1795‐1803.</Citation></Reference><Reference><Citation>Lai KN, Leung JC, Tang SC. Recent advances in the understanding and management of IgA nephropathy. F1000Res. 2016;5:F1000 Faculty Rev‐161.</Citation></Reference><Reference><Citation>Sinniah R. Heterogeneous IgA glomerulonephropathy in liver cirrhosis. Histopathology. 1984;8:947‐962.</Citation></Reference><Reference><Citation>Coppo R. The gut‐renal connection in IgA nephropathy. Semin Nephrol. 2018;38(5):504‐512.</Citation></Reference><Reference><Citation>Makita Y, Suzuki H, Kano T, et al. TLR9 activation induces aberrant IgA glycosylation via APRIL‐ and IL‐6‐mediated pathways in IgA nephropathy. Kidney Int. 2020;97(2):340‐349.</Citation></Reference><Reference><Citation>Ginès P, Krag A, Abraldes JG, Solà E, Fabrellas N, Kamath PS. Liver cirrhosis. Lancet. 2021;398(10308):1359‐1376.</Citation></Reference><Reference><Citation>Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. J Hepatol. 2019;70(1):151‐171.</Citation></Reference><Reference><Citation>Beste LA, Leipertz SL, Green PK, Dominitz JA, Ross D, Ioannou GN. Trends in burden of cirrhosis and hepatocellular carcinoma by underlying liver disease in US veterans, 2001–2013. Gastroenterology. 2015;149(6):1471‐1482.e5.</Citation></Reference><Reference><Citation>Flemming JA, Dewit Y, Mah JM, Saperia J, Groome PA, Booth CM. Incidence of cirrhosis in young birth cohorts in Canada from 1997 to 2016: a retrospective population‐based study. Lancet Gastroenterol Hepatol. 2019;4(3):217‐226.</Citation></Reference><Reference><Citation>Du Plessis J, Vanheel H, Janssen CE, et al. Activated intestinal macrophages in patients with cirrhosis release NO and IL‐6 that may disrupt intestinal barrier function. J Hepatol. 2013;58(6):1125‐1132.</Citation></Reference><Reference><Citation>Assimakopoulos SF, Tsamandas AC, Tsiaoussis GI, et al. Altered intestinal tight junctions' expression in patients with liver cirrhosis: a pathogenetic mechanism of intestinal hyperpermeability. Eur J Clin Investig. 2012;42(4):439‐446.</Citation></Reference><Reference><Citation>Voulgaris T, Tiniakos D, Karagiannakis D, et al. Alteration of small intestinal occludin and ZO‐1 expession in liver cirrhosis. Pathol Int. 2024;74(3):154‐156.</Citation></Reference><Reference><Citation>Moreno‐Navarrete JM, Sabater M, Ortega F, Ricart W, Fernandez‐Real JM. Circulating zonulin, a marker of intestinal permeability, is increased in association with obesity‐associated insulin resistance. PLoS One. 2012;7(5):e37160.</Citation></Reference><Reference><Citation>Tang Y, Forsyth CB, Farhadi A, et al. Nitric oxide‐mediated intestinal injury is required for alcohol‐induced gut leakiness and liver damage. Alcohol Clin Exp Res. 2009;33(7):1220‐1230.</Citation></Reference><Reference><Citation>Pijls KE, Jonkers DM, Elamin EE, Masclee AA, Koek GH. Intestinal epithelial barrier function in liver cirrhosis: an extensive review of the literature. Liver Int. 2013;33(10):1457‐1469.</Citation></Reference><Reference><Citation>Fukui H, Wiest R. Changes of intestinal functions in liver cirrhosis. Inflammatory Intestinal Dis. 2016;1(1):24‐40.</Citation></Reference><Reference><Citation>Ueta M, Kinoshita S. Innate immunity of the ocular surface. Brain Res Bull. 2010;81(2–3):219‐228.</Citation></Reference><Reference><Citation>Leonardi A, Bogacka E, Fauquert J‐L, et al. Ocular allergy: recognizing and diagnosing hypersensitivity disorders of the ocular surface. Allergy. 2012;67(11):1327‐1337.</Citation></Reference><Reference><Citation>Leonardi A, Motterle L, Bortolotti M. Allergy and the eye. Clin Exp Immunol. 2008;153(Supplement_1):17‐21.</Citation></Reference><Reference><Citation>Friedlaender MH. Ocular allergy. Curr Opin Allergy Clin Immunol. 2011;11(5):477‐482.</Citation></Reference><Reference><Citation>Miyazaki D, Fukagawa K, Okamoto S, et al. Epidemiological aspects of allergic conjunctivitis. Allergol Int. 2020;69(4):487‐495.</Citation></Reference><Reference><Citation>Meng Q, Nagarajan S, Son Y, Koutsoupias P, Bielory L. Asthma, oculonasal symptoms, and skin test sensitivity across National Health and nutrition examination surveys. Ann Allergy Asthma Immunol. 2016;116(2):118‐125.e5.</Citation></Reference><Reference><Citation>Mimura T, Ichinose T, Yamagami S, et al. Airborne particulate matter (PM2. 5) and the prevalence of allergic conjunctivitis in Japan. Sci Total Environ. 2014;487:493‐499.</Citation></Reference><Reference><Citation>Hughes J, Lackie P, Wilson S, Church M, McGill J. Reduced structural proteins in the conjunctival epithelium in allergic eye disease. Allergy. 2006;61(11):1268‐1274.</Citation></Reference><Reference><Citation>Ono SJ, Lane K. Comparison of effects of alcaftadine and olopatadine on conjunctival epithelium and eosinophil recruitment in a murine model of allergic conjunctivitis. Drug Des Devel Ther. 2011;5:77‐84.</Citation></Reference><Reference><Citation>Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II definition and classification report. Ocul Surf. 2017;15(3):276‐283.</Citation></Reference><Reference><Citation>Papas EB. The global prevalence of dry eye disease: a Bayesian view. Ophthalmic Physiol Opt. 2021;41(6):1254‐1266.</Citation></Reference><Reference><Citation>Dana R, Bradley JL, Guerin A, et al. Estimated prevalence and incidence of dry eye disease based on coding analysis of a large, all‐age United States health care system. Am J Ophthalmol. 2019;202:47‐54.</Citation></Reference><Reference><Citation>Gayton JL. Etiology, prevalence, and treatment of dry eye disease. Clin Ophthalmol. 2009;3:405‐412.</Citation></Reference><Reference><Citation>Stern ME, Schaumburg CS, Pflugfelder SC. Dry eye as a mucosal autoimmune disease. Int Rev Immunol. 2013;32(1):19‐41.</Citation></Reference><Reference><Citation>Leonardi A, Silva D, Perez Formigo D, et al. Management of ocular allergy. Allergy. 2019;74(9):1611‐1630.</Citation></Reference><Reference><Citation>Mantelli F, Massaro‐Giordano M, Macchi I, Lambiase A, Bonini S. The cellular mechanisms of dry eye: from pathogenesis to treatment. J Cell Physiol. 2013;228(12):2253‐2256.</Citation></Reference><Reference><Citation>Luo L, Li D‐Q, Doshi A, Farley W, Corrales RM, Pflugfelder SC. Experimental dry eye stimulates production of inflammatory cytokines and MMP‐9 and activates MAPK signaling pathways on the ocular surface. Invest Ophthalmol Vis Sci. 2004;45(12):4293‐4301.</Citation></Reference><Reference><Citation>Simmons KT, Xiao Y, Pflugfelder SC, de Paiva CS. Inflammatory response to lipopolysaccharide on the ocular surface in a murine dry eye model. Invest Ophthalmol Vis Sci. 2016;57(6):2443‐2451.</Citation></Reference><Reference><Citation>Li D‐Q, Lokeshwar BL, Solomon A, Monroy D, Ji Z, Pflugfelder SC. Regulation of MMP‐9 production by human corneal epithelial cells. Exp Eye Res. 2001;73(4):449‐459.</Citation></Reference><Reference><Citation>Pflugfelder SC, Farley W, Luo L, et al. Matrix metalloproteinase‐9 knockout confers resistance to corneal epithelial barrier disruption in experimental dry eye. Am J Pathol. 2005;166(1):61‐71.</Citation></Reference><Reference><Citation>Willis KA, Postnikoff CK, Freeman A, et al. The closed eye harbours a unique microbiome in dry eye disease. Sci Rep. 2020;10(1):1‐10.</Citation></Reference><Reference><Citation>Andersson J, Vogt JK, Dalgaard MD, Pedersen O, Holmgaard K, Heegaard S. Ocular surface microbiota in patients with aqueous tear‐deficient dry eye. Ocul Surf. 2021;19:210‐217.</Citation></Reference><Reference><Citation>Zhang Z, Zou X, Xue W, Zhang P, Wang S, Zou H. Ocular surface microbiota in diabetic patients with dry eye disease. Invest Ophthalmol Vis Sci. 2021;62(12):13.</Citation></Reference><Reference><Citation>Abbasi MA, Chertow GM, Hall YN. End‐stage renal disease. BMJ Clinical Evidence. 2010;2010:2002.</Citation></Reference><Reference><Citation>Orr NI, McDonald SP, McTaggart S, Henning P, Craig JC. Frequency, etiology and treatment of childhood end‐stage kidney disease in Australia and New Zealand. Pediatr Nephrol. 2009;24:1719‐1726.</Citation></Reference><Reference><Citation>Hsu C‐y, Go AS, McCulloch CE, Darbinian J, Iribarren C. Exploring secular trends in the likelihood of receiving treatment for end‐stage renal disease. Clin J Am Soc Nephrol. 2007;2(1):81‐88.</Citation></Reference><Reference><Citation>Hsu C‐y, McCulloch CE, Iribarren C, Darbinian J, Go AS. Body mass index and risk for end‐stage renal disease. Ann Intern Med. 2006;144(1):21‐28.</Citation></Reference><Reference><Citation>Orth SR, Stöckmann A, Conradt C, et al. Smoking as a risk factor for end‐stage renal failure in men with primary renal disease. Kidney Int. 1998;54(3):926‐931.</Citation></Reference><Reference><Citation>Hsu C‐y, Iribarren C, McCulloch CE, Darbinian J, Go AS. Risk factors for end‐stage renal disease: 25‐year follow‐up. Arch Intern Med. 2009;169(4):342‐350.</Citation></Reference><Reference><Citation>Vaziri ND, Goshtasbi N, Yuan J, et al. Uremic plasma impairs barrier function and depletes the tight junction protein constituents of intestinal epithelium. Am J Nephrol. 2012;36(5):438‐443.</Citation></Reference><Reference><Citation>Feroze U, Kalantar‐Zadeh K, Sterling KA, et al. Examining associations of circulating endotoxin with nutritional status, inflammation, and mortality in hemodialysis patients. J Ren Nutr. 2012;22(3):317‐326.</Citation></Reference><Reference><Citation>Vaziri ND, Wong J, Pahl M, et al. Chronic kidney disease alters intestinal microbial flora. Kidney Int. 2013;83(2):308‐315.</Citation></Reference><Reference><Citation>Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. Lancet. 2011;377(9773):1276‐1287.</Citation></Reference><Reference><Citation>Ahlborg HG, Rosengren BE, Järvinen TL, et al. Prevalence of osteoporosis and incidence of hip fracture in women‐secular trends over 30 years. BMC Musculoskelet Disord. 2010;11:1‐7.</Citation></Reference><Reference><Citation>Black D, Rosen C. Clinical practice. Postmenopausal osteoporosis. N Engl J Med. 2016;374:254‐262.</Citation></Reference><Reference><Citation>Bijelic R, Milicevic S, Balaban J. Risk factors for osteoporosis in postmenopausal women. Medical Arch. 2017;71(1):25.</Citation></Reference><Reference><Citation>Kim J‐M, Lin C, Stavre Z, Greenblatt MB, Shim J‐H. Osteoblast‐osteoclast communication and bone homeostasis. Cells. 2020;9(9):2073.</Citation></Reference><Reference><Citation>Wang J, Wang Y, Gao W, et al. Diversity analysis of gut microbiota in osteoporosis and osteopenia patients. PeerJ. 2017;5:e3450.</Citation></Reference><Reference><Citation>Wallimann A, Magrath W, Pugliese B, et al. Butyrate inhibits osteoclast activity in vitro and regulates systemic inflammation and bone healing in a murine osteotomy model compared to antibiotic‐treated mice. Mediat Inflamm. 2021;2021:8817421.</Citation></Reference><Reference><Citation>Wallimann A, Hildebrand M, Groeger D, et al. An exopolysaccharide produced by Bifidobacterium longum 35624(R) inhibits osteoclast formation via a TLR2‐dependent mechanism. Calcif Tissue Int. 2021;108(5):654‐666.</Citation></Reference><Reference><Citation>Hao M‐l, Wang G‐y, Zuo X‐q, Qu C‐j, Yao B‐c, Wang D‐l. Gut microbiota: an overlooked factor that plays a significant role in osteoporosis. J Int Med Res. 2019;47(9):4095‐4103.</Citation></Reference><Reference><Citation>Wang N, Ma S, Fu L. Gut microbiota dysbiosis as one cause of osteoporosis by impairing intestinal barrier function. Calcif Tissue Int. 2022;110:225‐235.</Citation></Reference><Reference><Citation>Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497‐506.</Citation></Reference><Reference><Citation>Zayet S, Lepiller Q, Zahra H, et al. Clinical features of COVID‐19 and influenza: a comparative study on Nord Franche‐Comte cluster. Microbes Infect. 2020;22(9):481‐488.</Citation></Reference><Reference><Citation>Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727‐733.</Citation></Reference><Reference><Citation>WHO. WHO Director‐General's opening remarks at the media briefing on COVID‐19. 2020 https://www.who.int/dg/speeches/detail/who‐director‐general‐s‐opening‐remarks‐at‐the‐media‐briefing‐on‐covid‐19‐‐‐11‐march‐2020</Citation></Reference><Reference><Citation>WHO. WHO coronavirus disease (COVID‐19) dashboard. 2023 Accessed 2023‐07‐11. https://covid19.who.int</Citation></Reference><Reference><Citation>Lamers MM, Beumer J, van der Vaart J, et al. SARS‐CoV‐2 productively infects human gut enterocytes. Science. 2020;369(6499):50‐54.</Citation></Reference><Reference><Citation>Dumas A, Bernard L, Poquet Y, Lugo‐Villarino G, Neyrolles O. The role of the lung microbiota and the gut–lung axis in respiratory infectious diseases. Cell Microbiol. 2018;20(12):e12966.</Citation></Reference><Reference><Citation>Yazici D, Cagan E, Tan G, et al. Disrupted epithelial permeability as a predictor of severe COVID‐19 development. Allergy. 2023;78:2644‐2658.</Citation></Reference><Reference><Citation>Giron LB, Dweep H, Yin X, et al. Plasma markers of disrupted gut permeability in severe COVID‐19 patients. Front Immunol. 2021;12:686240.</Citation></Reference><Reference><Citation>Lunjani N, Albrich WC, Suh N, et al. Higher levels of bacterial DNA in serum associate with severe and fatal COVID‐19. Allergy. 2022;77(4):1312‐1314.</Citation></Reference><Reference><Citation>Albrich WC, Ghosh TS, Ahearn‐Ford S, et al. A high‐risk gut microbiota configuration associates with fatal hyperinflammatory immune and metabolic responses to SARS‐CoV‐2. Gut Microbes. 2022;14(1):2073131.</Citation></Reference><Reference><Citation>Li J, Ghosh TS, McCann R, et al. Robust cross‐cohort gut microbiome associations with COVID‐19 severity. Gut Microbes. 2023;15(1):2242615.</Citation></Reference><Reference><Citation>Ballering AV, van Zon SKR, Olde Hartman TC, Rosmalen JGM, Lifelines Corona Research I. Persistence of somatic symptoms after COVID‐19 in The Netherlands: an observational cohort study. Lancet. 2022;400(10350):452‐461.</Citation></Reference><Reference><Citation>Choutka J, Jansari V, Hornig M, Iwasaki A. Unexplained post‐acute infection syndromes. Nat Med. 2022;28(5):911‐923.</Citation></Reference><Reference><Citation>O'Mahony L, Buwalda T, Blair M, et al. Impact of Long COVID on health and quality of life. HRB Open Res. 2022;5:31.</Citation></Reference><Reference><Citation>Unstersmayr E, Venter C, Smith P, et al. Immune mechanisms underpinning long COVID: collegium internationale allergologicum update 2024. Int Arch Allergy Immunol. 2024;22:1‐14.</Citation></Reference><Reference><Citation>Altmann DM, Whettlock EM, Liu S, Arachchillage DJ, Boyton RJ. The immunology of long COVID. Nat Rev Immunol. 2023;23(10):618‐634.</Citation></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133‐146.</Citation></Reference><Reference><Citation>Cervia‐Hasler C, Bruningk SC, Hoch T, et al. Persistent complement dysregulation with signs of thromboinflammation in active Long Covid. Science. 2024;383(6680):eadg7942.</Citation></Reference><Reference><Citation>Tang WH, Kitai T, Hazen SL. Gut microbiota in cardiovascular health and disease. Circ Res. 2017;120(7):1183‐1196.</Citation></Reference><Reference><Citation>Verhaar BJH, Prodan A, Nieuwdorp M, Muller M. Gut microbiota in hypertension and atherosclerosis: a review. Nutrients. 2020;12(10):2982.</Citation></Reference><Reference><Citation>Khalesi S, Sun J, Buys N, Jayasinghe R. Effect of probiotics on blood pressure: a systematic review and meta‐analysis of randomized, controlled trials. Hypertension. 2014;64(4):897‐903.</Citation></Reference><Reference><Citation>Aguilar EC, Leonel AJ, Teixeira LG, et al. Butyrate impairs atherogenesis by reducing plaque inflammation and vulnerability and decreasing NFkappaB activation. Nutr Metab Cardiovasc Dis. 2014;24(6):606‐613.</Citation></Reference><Reference><Citation>Dayang EZ, Plantinga J, Ter Ellen B, van Meurs M, Molema G, Moser J. Identification of LPS‐activated endothelial subpopulations with distinct inflammatory phenotypes and regulatory signaling mechanisms. Front Immunol. 2019;10:1169.</Citation></Reference><Reference><Citation>Zhang WQ, Wang YJ, Zhang A, et al. TMA/TMAO in hypertension: novel horizons and potential therapies. J Cardiovasc Transl Res. 2021;14(6):1117‐1124.</Citation></Reference><Reference><Citation>Gallo A, Macerola N, Favuzzi AM, Nicolazzi MA, Gasbarrini A, Montalto M. The gut in heart failure: current knowledge and novel Frontiers. Med Princ Pract. 2022;31(3):203‐214.</Citation></Reference><Reference><Citation>Mamic P, Snyder M, Tang WHW. Gut microbiome‐based management of patients with heart failure: JACC review topic of the week. J Am Coll Cardiol. 2023;81(17):1729‐1739.</Citation></Reference><Reference><Citation>Anderson KM, Ferranti EP, Alagha EC, Mykityshyn E, French CE, Reilly CM. The heart and gut relationship: a systematic review of the evaluation of the microbiome and trimethylamine‐N‐oxide (TMAO) in heart failure. Heart Fail Rev. 2022;27(6):2223‐2249.</Citation></Reference><Reference><Citation>Gil‐Cruz C, Perez‐Shibayama C, De Martin A, et al. Microbiota‐derived peptide mimics drive lethal inflammatory cardiomyopathy. Science. 2019;366(6467):881‐886.</Citation></Reference><Reference><Citation>Violi F, Castellani V, Menichelli D, Pignatelli P, Pastori D. Gut barrier dysfunction and endotoxemia in heart failure: a dangerous connubium? Am Heart J. 2023;264:40‐48.</Citation></Reference><Reference><Citation>Romano KA, Nemet I, Prasad Saha P, et al. Gut microbiota‐generated Phenylacetylglutamine and heart failure. Circ Heart Fail. 2023;16(1):e009972.</Citation></Reference><Reference><Citation>Wang YC, Koay YC, Pan C, et al. Indole‐3‐propionic acid protects against heart failure with preserved ejection fraction. Circ Res. 2024;134(4):371‐389.</Citation></Reference><Reference><Citation>Gawałko M, Agbaedeng TA, Saljic A, et al. Gut microbiota, dysbiosis and atrial fibrillation. Arrhythmogenic mechanisms and potential clinical implications. Cardiovasc Res. 2022;118(11):2415‐2427.</Citation></Reference><Reference><Citation>Zhang Y, Zhang S, Li B, et al. Gut microbiota dysbiosis promotes age‐related atrial fibrillation by lipopolysaccharide and glucose‐induced activation of NLRP3‐inflammasome. Cardiovasc Res. 2022;118(3):785‐797.</Citation></Reference><Reference><Citation>Parker J, O'Brien C, Hawrelak J, Gersh FL. Polycystic ovary syndrome: an evolutionary adaptation to lifestyle and the environment. Int J Environ Res Public Health. 2022;19(3):1336.</Citation></Reference><Reference><Citation>Azziz R, Carmina E, Chen Z, et al. Polycystic ovary syndrome. Nat Rev Dis Primers. 2016;2:16057.</Citation></Reference><Reference><Citation>Goodarzi MO, Dumesic DA, Chazenbalk G, Azziz R. Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol. 2011;7(4):219‐231.</Citation></Reference><Reference><Citation>Diamanti‐Kandarakis E, Piperi C. Genetics of polycystic ovary syndrome: searching for the way out of the labyrinth. Hum Reprod Update. 2005;11(6):631‐643.</Citation></Reference><Reference><Citation>Yang R, Li Q, Zhou Z, et al. Changes in the prevalence of polycystic ovary syndrome in China over the past decade. Lancet Reg Health West Pac. 2022;25:100494.</Citation></Reference><Reference><Citation>Vatier C, Christin‐Maitre S. Epigenetic/circadian clocks and PCOS. Hum Reprod. 2024;39(6):1167‐1175.</Citation></Reference><Reference><Citation>Teede HJ, Tay CT, Laven J, et al. Recommendations from the 2023 international evidence‐based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril. 2023;120(4):767‐793.</Citation></Reference><Reference><Citation>Hirschberg AL. Polycystic ovary syndrome, obesity and reproductive implications. Womens Health (Lond). 2009;5(5):529‐540; quiz 541–522.</Citation></Reference><Reference><Citation>Turnbaugh PJ, Ridaura VK, Faith JJ, Rey FE, Knight R, Gordon JI. The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice. Sci Transl Med. 2009;1(6):6ra14.</Citation></Reference><Reference><Citation>Portincasa P, Bonfrate L, Khalil M, et al. Intestinal barrier and permeability in health, obesity and NAFLD. Biomedicine. 2021;10(1):83.</Citation></Reference><Reference><Citation>Piazza MJ, Urbanetz AA. Environmental toxins and the impact of other endocrine disrupting chemicals in women's reproductive health. JBRA Assist Reprod. 2019;23(2):154‐164.</Citation></Reference><Reference><Citation>Cani PD, Neyrinck AM, Fava F, et al. Selective increases of bifidobacteria in gut microflora improve high‐fat‐diet‐induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia. 2007;50(11):2374‐2383.</Citation></Reference><Reference><Citation>Basu BR, Chowdhury O, Saha SK. Possible link between stress‐related factors and altered body composition in women with polycystic ovarian syndrome. J Hum Reprod Sci. 2018;11(1):10‐18.</Citation></Reference><Reference><Citation>March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ, Davies MJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod. 2010;25(2):544‐551.</Citation></Reference><Reference><Citation>Wu XK, Zhou SY, Liu JX, et al. Selective ovary resistance to insulin signaling in women with polycystic ovary syndrome. Fertil Steril. 2003;80(4):954‐965.</Citation></Reference><Reference><Citation>Book CB, Dunaif A. Selective insulin resistance in the polycystic ovary syndrome. J Clin Endocrinol Metab. 1999;84(9):3110‐3116.</Citation></Reference><Reference><Citation>Guo Y, Qi Y, Yang X, et al. Association between polycystic ovary syndrome and gut microbiota. PLoS One. 2016;11(4):e0153196.</Citation></Reference><Reference><Citation>Li P, Shuai P, Shen S, et al. Perturbations in gut microbiota composition in patients with polycystic ovary syndrome: a systematic review and meta‐analysis. BMC Med. 2023;21(1):302.</Citation></Reference><Reference><Citation>Zou Y, Liao R, Cheng R, Chung H, Zhu H, Huang Y. Alterations of gut microbiota biodiversity and relative abundance in women with PCOS: a systematic review and meta‐analysis. Microb Pathog. 2023;184:106370.</Citation></Reference><Reference><Citation>Qi X, Yun C, Sun L, et al. Gut microbiota‐bile acid‐interleukin‐22 axis orchestrates polycystic ovary syndrome. Nat Med. 2019;25(8):1225‐1233.</Citation></Reference><Reference><Citation>Gibson GR, Beatty ER, Wang X, Cummings JH. Selective stimulation of bifidobacteria in the human colon by oligofructose and inulin. Gastroenterology. 1995;108(4):975‐982.</Citation></Reference><Reference><Citation>Cani PD, Bibiloni R, Knauf C, et al. Changes in gut microbiota control metabolic endotoxemia‐induced inflammation in high‐fat diet‐induced obesity and diabetes in mice. Diabetes. 2008;57(6):1470‐1481.</Citation></Reference><Reference><Citation>Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JM, Sattar N. Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab. 2001;86(6):2453‐2455.</Citation></Reference><Reference><Citation>Younis A, Hawkins K, Mahini H, Butler W, Garelnabi M. Serum tumor necrosis factor‐alpha, interleukin‐6, monocyte chemotactic protein‐1 and paraoxonase‐1 profiles in women with endometriosis, PCOS, or unexplained infertility. J Assist Reprod Genet. 2014;31(11):1445‐1451.</Citation></Reference><Reference><Citation>Xu Y, Qiao J. Association of insulin resistance and elevated androgen levels with polycystic ovarian syndrome (PCOS): a review of literature. J Healthc Eng. 2022;2022:9240569.</Citation></Reference><Reference><Citation>Tremellen K, Pearce K. Dysbiosis of gut microbiota (DOGMA)–a novel theory for the development of polycystic ovarian syndrome. Med Hypotheses. 2012;79(1):104‐112.</Citation></Reference><Reference><Citation>Sonnenburg JL, Backhed F. Diet‐microbiota interactions as moderators of human metabolism. Nature. 2016;535(7610):56‐64.</Citation></Reference><Reference><Citation>Carvalho BM, Saad MJ. Influence of gut microbiota on subclinical inflammation and insulin resistance. Mediat Inflamm. 2013;2013:986734.</Citation></Reference><Reference><Citation>Campos‐Alberto E, Hirose T, Napatalung L, Ohyama M. Prevalence, comorbidities, and treatment patterns of Japanese patients with alopecia areata: a descriptive study using Japan medical data center claims database. J Dermatol. 2023;50(1):37‐45.</Citation></Reference><Reference><Citation>Glickman JW, Dubin C, Dahabreh D, et al. An integrated scalp and blood biomarker approach suggests the systemic nature of alopecia areata. Allergy. 2021;76(10):3053‐3065.</Citation></Reference><Reference><Citation>Glickman JW, Dubin C, Renert‐Yuval Y, et al. Cross‐sectional study of blood biomarkers of patients with moderate to severe alopecia areata reveals systemic immune and cardiovascular biomarker dysregulation. J Am Acad Dermatol. 2021;84(2):370‐380.</Citation></Reference><Reference><Citation>Pinto D, Sorbellini E, Marzani B, Rucco M, Giuliani G, Rinaldi F. Scalp bacterial shift in Alopecia areata. PLoS One. 2019;14(4):e0215206.</Citation></Reference><Reference><Citation>Farahmand S. Microbiome of compromised skin. In: Dayan N, ed. Skin microbiome handbook: from basic research to product development. Wiley‐Scrivener; 2020:143‐169.</Citation></Reference><Reference><Citation>Parisi R, Yiu Z. The worldwide epidemiology of rosacea. Br J Dermatol. 2018;179(2):239‐240.</Citation></Reference><Reference><Citation>Medgyesi B, Dajnoki Z, Béke G, et al. Rosacea is characterized by a profoundly diminished skin barrier. J Invest Dermatol. 2020;140(10):1938‐1950.e5.</Citation></Reference><Reference><Citation>Deng Z, Chen M, Xie H, et al. Claudin reduction may relate to an impaired skin barrier in rosacea. J Dermatol. 2019;46(4):314‐321.</Citation></Reference><Reference><Citation>Rainer BM, Thompson KG, Antonescu C, et al. Characterization and analysis of the skin microbiota in rosacea: a case–control study. Am J Clin Dermatol. 2020;21:139‐147.</Citation></Reference><Reference><Citation>Gonçalves GAP, Brito MMC, Salathiel AM, Ferraz TS, Alves D, Roselino AMF. Incidence of pemphigus vulgaris exceeds that of pemphigus foliaceus in a region where pemphigus foliaceus is endemic: analysis of a 21‐year historical series. An Bras Dermatol. 2011;86:1109‐1112.</Citation></Reference><Reference><Citation>Hasan S, Ahmed S, Khan NI, Tarannum F. Pemphigus vulgaris—a case report and detailed review of literature. Indian J Dentistry. 2011;2(3):113‐119.</Citation></Reference><Reference><Citation>Hashimoto K, Lever WF. An electron microscopic study on pemphigus vulgaris of the mouth and the skin with special reference to the intercellular cement. J Invest Dermatol. 1967;48(6):540‐552.</Citation></Reference><Reference><Citation>Timoteo RP, da Silva MV, Miguel CB, et al. Th1/Th17‐related cytokines and chemokines and their implications in the pathogenesis of pemphigus vulgaris. Mediat Inflamm. 2017;2017:7151285.</Citation></Reference><Reference><Citation>Scaglione GL, Fania L, De Paolis E, et al. Evaluation of cutaneous, oral and intestinal microbiota in patients affected by pemphigus and bullous pemphigoid: a pilot study. Exp Mol Pathol. 2020;112:104331.</Citation></Reference><Reference><Citation>Jacobs RL, Freedman PM, Boswell RN. Nonallergic rhinitis with eosinophilia (NARES syndrome): clinical and immunologic presentation. J Allergy Clin Immunol. 1981;67(4):253‐262.</Citation></Reference><Reference><Citation>Bousquet J, Fokkens W, Burney P, et al. Important research questions in allergy and related diseases: nonallergic rhinitis: a GA2LEN paper. Allergy. 2008;63(7):842‐853.</Citation></Reference><Reference><Citation>Settipane RA, Lieberman P. Update on nonallergic rhinitis. Ann Allergy Asthma Immunol. 2001;86(5):494‐508.</Citation></Reference><Reference><Citation>Ramanathan M Jr, London NR Jr, Tharakan A, et al. Airborne particulate matter induces nonallergic eosinophilic sinonasal inflammation in mice. Am J Respir Cell Mol Biol. 2017;57(1):59‐65.</Citation></Reference><Reference><Citation>Hosoda Y, Yamaguchi M, Hiraga Y. Global epidemiology of sarcoidosis: what story do prevalence and incidence tell us? Clin Chest Med. 1997;18(4):681‐694.</Citation></Reference><Reference><Citation>Divertie MB, Cassan SM, Brown AL Jr. Ultrastructural morphometry of the blood‐air barrier in pulmonary sarcoidosis. Chest. 1976;69(2):154‐157.</Citation></Reference><Reference><Citation>Hermans C, Petrek M, Kolek V, et al. Serum Clara cell protein (CC16), a marker of the integrity of the air‐blood barrier in sarcoidosis. Eur Respir J. 2001;18(3):507‐514.</Citation></Reference><Reference><Citation>Bargagli E, Mazzi A, Rottoli P. Markers of inflammation in sarcoidosis: blood, urine, BAL, sputum, and exhaled gas. Clin Chest Med. 2008;29(3):445‐458.</Citation></Reference><Reference><Citation>Kramer MS, Lane DA. Aminorex, dexfenfluramine, and primary pulmonary hypertension. J Clin Epidemiol. 1998;51(4):361‐364.</Citation></Reference><Reference><Citation>George MG, Schieb LJ, Ayala C, Talwalkar A, Levant S. Pulmonary hypertension surveillance: United States, 2001 to 2010. Chest. 2014;146(2):476‐495.</Citation></Reference><Reference><Citation>Rafikova O, James J, Eccles CA, et al. Early progression of pulmonary hypertension in the monocrotaline model in males is associated with increased lung permeability. Biol Sex Differ. 2020;11(1):1‐9.</Citation></Reference><Reference><Citation>Chen J, Zhou D, Miao J, et al. Microbiome and metabolome dysbiosis of the gut‐lung axis in pulmonary hypertension. Microbiol Res. 2022;265:127205.</Citation></Reference><Reference><Citation>Quon BS, Aitken ML. Cystic fibrosis: what to expect now in the early adult years. Paediatr Respir Rev. 2012;13(4):206‐214.</Citation></Reference><Reference><Citation>Gregory P. Gastrointestinal pH, motility/transit and permeability in cystic fibrosis. J Pediatr Gastroenterol Nutr. 1996;23(5):513‐523.</Citation></Reference><Reference><Citation>Werlin SL, Benuri‐Silbiger I, Kerem E, et al. Evidence of intestinal inflammation in patients with cystic fibrosis. J Pediatr Gastroenterol Nutr. 2010;51(3):304‐308.</Citation></Reference><Reference><Citation>Bruzzese E, Callegari ML, Raia V, et al. Disrupted intestinal microbiota and intestinal inflammation in children with cystic fibrosis and its restoration with lactobacillus GG: a randomised clinical trial. PLoS One. 2014;9(2):e87796.</Citation></Reference><Reference><Citation>Wu L, Zhang SQ, Zhao L, Ren ZH, Hu CY. Global, regional, and national burden of periodontitis from 1990 to 2019: results from the global burden of disease study 2019. J Periodontol. 2022;93(10):1445‐1454.</Citation></Reference><Reference><Citation>Zhang S, Yu N, Arce RM. Periodontal inflammation: integrating genes and dysbiosis. Periodontol. 2020;82(1):129‐142.</Citation></Reference><Reference><Citation>Hvid‐Jensen F, Pedersen L, Drewes AM, Sørensen HT, Funch‐Jensen P. Incidence of adenocarcinoma among patients with Barrett's esophagus. N Engl J Med. 2011;365(15):1375‐1383.</Citation></Reference><Reference><Citation>Kool B, Chandra D, Fitzharris P. Adult food‐induced anaphylaxis hospital presentations in New Zealand. Postgrad Med J. 2016;92(1093):640‐644.</Citation></Reference><Reference><Citation>Rudders SA, Arias SA, Camargo CA. Trends in hospitalizations for food‐induced anaphylaxis in US children, 2000–2009. J Allergy Clin Immunol. 2014;134(4):960‐962.e3.</Citation></Reference><Reference><Citation>Ruffner MA, Wang KY, Dudley JW, et al. Elevated atopic comorbidity in patients with food protein–induced enterocolitis. J Allergy Clin Immunol. 2020;8(3):1039‐1046.</Citation></Reference><Reference><Citation>Berin MC, Lozano‐Ojalvo D, Agashe C, Baker MG, Bird JA, Nowak‐Wegrzyn A. Acute FPIES reactions are associated with an IL‐17 inflammatory signature. J Allergy Clin Immunol. 2021;148(3):895‐901.e6.</Citation></Reference><Reference><Citation>Boyer J, Scuderi V. P504 comparison of the gut microbiome between food protein‐induced enterocolitis sydrome (FPIES) infants and allergy‐free infants. Ann Allergy Asthma Immunol. 2017;119(5):e3.</Citation></Reference><Reference><Citation>Weimers P, Ankersen DV, Lophaven S, et al. Incidence and prevalence of microscopic colitis between 2001 and 2016: a Danish nationwide cohort study. J Crohn's Colitis. 2020;14(12):1717‐1723.</Citation></Reference><Reference><Citation>Barmeyer C, Erko I, Fromm A, et al. Ion transport and barrier function are disturbed in microscopic colitis. Ann N Y Acad Sci. 2012;1258(1):143‐148.</Citation></Reference><Reference><Citation>Morgan DM, Cao Y, Miller K, et al. Microscopic colitis is characterized by intestinal dysbiosis. Clin Gastroenterol Hepatol. 2020;18(4):984‐986.</Citation></Reference><Reference><Citation>Okui T. An age‐period‐cohort analysis for prevalence of common psychiatric disorders in Japan, 1999–2017. Soc Psychiatry Psychiatr Epidemiol. 2021;56:639‐648.</Citation></Reference><Reference><Citation>Lennon E, Maharshak N, Elloumi H, Borst L, Plevy S, Moeser AJ. Early life stress triggers persistent colonic barrier dysfunction and exacerbates colitis in adult IL‐10−/− mice. Inflamm Bowel Dis. 2013;19(4):712‐719.</Citation></Reference><Reference><Citation>Bentzen J, Meulengracht Flachs E, Stenager E, Brønnum‐Hansen H, Koch‐Henriksen N. Prevalence of multiple sclerosis in Denmark 1950–2005. Mult Scler J. 2010;16(5):520‐525.</Citation></Reference><Reference><Citation>Grassivaro F, Puthenparampil M, Pengo M, et al. Multiple sclerosis incidence and prevalence trends in the province of Padua, Northeast Italy, 1965–2018. Neuroepidemiology. 2019;52(1–2):41‐46.</Citation></Reference><Reference><Citation>Camara‐Lemarroy CR, Silva C, Greenfield J, Liu W‐Q, Metz LM, Yong VW. Biomarkers of intestinal barrier function in multiple sclerosis are associated with disease activity. Mult Scler J. 2020;26(11):1340‐1350.</Citation></Reference><Reference><Citation>Camara‐Lemarroy CR, Metz L, Meddings JB, Sharkey KA, Wee YV. The intestinal barrier in multiple sclerosis: implications for pathophysiology and therapeutics. Brain. 2018;141(7):1900‐1916.</Citation></Reference><Reference><Citation>Fang F, Valdimarsdóttir U, Bellocco R, et al. Amyotrophic lateral sclerosis in Sweden, 1991–2005. Arch Neurol. 2009;66(4):515‐519.</Citation></Reference><Reference><Citation>Xu L, Liu T, Liu L, et al. Global variation in prevalence and incidence of amyotrophic lateral sclerosis: a systematic review and meta‐analysis. J Neurol. 2020;267:944‐953.</Citation></Reference><Reference><Citation>Wu S, Yi J, Yg Z, Zhou J, Sun J. Leaky intestine and impaired microbiome in an amyotrophic lateral sclerosis mouse model. Physiol Rep. 2015;3(4):e12356.</Citation></Reference><Reference><Citation>Cindoruk M, Tuncer C, Dursun A, et al. Increased colonic intraepithelial lymphocytes in patients with Hashimoto's thyroiditis. J Clin Gastroenterol. 2002;34(3):237‐239.</Citation></Reference><Reference><Citation>Ishaq HM, Mohammad IS, Guo H, et al. Molecular estimation of alteration in intestinal microbial composition in Hashimoto's thyroiditis patients. Biomed Pharmacother. 2017;95:865‐874.</Citation></Reference><Reference><Citation>Alonso MD, Llorca J, Martinez‐Vazquez F, et al. Systemic lupus erythematosus in northwestern Spain: a 20‐year epidemiologic study. Medicine. 2011;90(5):350‐358.</Citation></Reference><Reference><Citation>Silverman GJ, Azzouz DF, Alekseyenko AV. Systemic lupus erythematosus and dysbiosis in the microbiome: cause or effect or both? Curr Opin Immunol. 2019;61:80‐85.</Citation></Reference><Reference><Citation>Dehner C, Fine R, Kriegel MA. The microbiome in systemic autoimmune disease–mechanistic insights from recent studies. Curr Opin Rheumatol. 2019;31(2):201.</Citation></Reference><Reference><Citation>Bakland G, Nossent HC, Gran JT. Incidence and prevalence of ankylosing spondylitis in northern Norway. Arthritis Care Res. 2005;53(6):850‐855.</Citation></Reference><Reference><Citation>Ciccia F, Guggino G, Rizzo A, et al. Dysbiosis and zonulin upregulation alter gut epithelial and vascular barriers in patients with ankylosing spondylitis. Ann Rheum Dis. 2017;76(6):1123‐1132.</Citation></Reference><Reference><Citation>Catanoso M, Macchioni P, Boiardi L, et al. Epidemiology of granulomatosis with polyangiitis (Wegener' s granulomatosis) in Northern Italy: a 15‐year population‐based study. Semin Arthritis Rheum. 2014;44:202‐207.</Citation></Reference><Reference><Citation>Grayson PC, Steiling K, Platt M, et al. Brief report: defining the nasal transcriptome in granulomatosis with Polyangiitis (Wegener's). Arthritis Rheum. 2015;67(8):2233‐2239.</Citation></Reference><Reference><Citation>Rhee RL, Sreih AG, Najem CE, et al. Characterisation of the nasal microbiota in granulomatosis with polyangiitis. Ann Rheum Dis. 2018;77(10):1448‐1453.</Citation></Reference><Reference><Citation>Grønbæk L, Vilstrup H, Jepsen P. Autoimmune hepatitis in Denmark: incidence, prevalence, prognosis, and causes of death. A nationwide registry‐based cohort study. J Hepatol. 2014;60(3):612‐617.</Citation></Reference><Reference><Citation>Tanaka A, Mori M, Matsumoto K, Ohira H, Tazuma S, Takikawa H. Increase trend in the prevalence and male‐to‐female ratio of primary biliary cholangitis, autoimmune hepatitis, and primary sclerosing cholangitis in Japan. Hepatol Res. 2019;49(8):881‐889.</Citation></Reference><Reference><Citation>Lin R, Zhou L, Zhang J, Wang B. Abnormal intestinal permeability and microbiota in patients with autoimmune hepatitis. Int J Clin Exp Pathol. 2015;8(5):5153.</Citation></Reference><Reference><Citation>Zouboulis CC. Epidemiology of Adamantiades‐Behçet's disease. Ann Med Interne. 1999;150(6):488‐498.</Citation></Reference><Reference><Citation>Fresko I, Hamuryudan V, Demir M, et al. Intestinal permeability in Behcet's syndrome. Ann Rheum Dis. 2001;60(1):65‐66.</Citation></Reference><Reference><Citation>Shimizu J, Kubota T, Takada E, et al. Bifidobacteria abundance‐featured gut microbiota compositional change in patients with Behcet's disease. PLoS One. 2016;11(4):e0153746.</Citation></Reference><Reference><Citation>Consolandi C, Turroni S, Emmi G, et al. Behçet's syndrome patients exhibit specific microbiome signature. Autoimmun Rev. 2015;14(4):269‐276.</Citation></Reference><Reference><Citation>Widdifield J, Paterson JM, Bernatsky S, et al. The epidemiology of rheumatoid arthritis in Ontario, Canada. Arthritis Rheum. 2014;66(4):786‐793.</Citation></Reference><Reference><Citation>Tajik N, Frech M, Schulz O, et al. Targeting zonulin and intestinal epithelial barrier function to prevent onset of arthritis. Nat Commun. 2020;11(1):1995.</Citation></Reference><Reference><Citation>Loeser RF, Arbeeva L, Kelley K, et al. Association of increased serum lipopolysaccharide, but not microbial dysbiosis, with obesity‐related osteoarthritis. Arthritis Rheum. 2022;74(2):227‐236.</Citation></Reference><Reference><Citation>Chen J, Wang A, Wang Q. Dysbiosis of the gut microbiome is a risk factor for osteoarthritis in older female adults: a case control study. BMC Bioinform. 2021;22(1):1‐11.</Citation></Reference><Reference><Citation>Pereira M, Carreira H, Lunet N, Azevedo A. Trends in prevalence of diabetes mellitus and mean fasting glucose in Portugal (1987–2009): a systematic review. Public Health. 2014;128(3):214‐221.</Citation></Reference><Reference><Citation>Bosi E, Molteni L, Radaelli M, et al. Increased intestinal permeability precedes clinical onset of type 1 diabetes. Diabetologia. 2006;49:2824‐2827.</Citation></Reference><Reference><Citation>Sapone A, De Magistris L, Pietzak M, et al. Zonulin upregulation is associated with increased gut permeability in subjects with type 1 diabetes and their relatives. Diabetes. 2006;55(5):1443‐1449.</Citation></Reference><Reference><Citation>Westerholm‐Ormio M, Vaarala O, Pi P, Ilonen J, Savilahti E. Immunologic activity in the small intestinal mucosa of pediatric patients with type 1 diabetes. Diabetes. 2003;52(9):2287‐2295.</Citation></Reference><Reference><Citation>Harbison JE, Roth‐Schulze AJ, Giles LC, et al. Gut microbiome dysbiosis and increased intestinal permeability in children with islet autoimmunity and type 1 diabetes: a prospective cohort study. Pediatr Diabetes. 2019;20(5):574‐583.</Citation></Reference><Reference><Citation>Sharma S, Tripathi P. Gut microbiome and type 2 diabetes: where we are and where to go? J Nutr Biochem. 2019;63:101‐108.</Citation></Reference><Reference><Citation>Flegal KM, Carroll MD, Kuczmarski RJ, Johnson CL. Overweight and obesity in the United States: prevalence and trends, 1960–1994. Int J Obes. 1998;22(1):39‐47.</Citation></Reference><Reference><Citation>Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999–2008. JAMA. 2010;303(3):235‐241.</Citation></Reference><Reference><Citation>Ogden CL, Carroll MD, Curtin LR, Lamb MM, Flegal KM. Prevalence of high body mass index in US children and adolescents, 2007–2008. JAMA. 2010;303(3):242‐249.</Citation></Reference><Reference><Citation>Little TJ, Cvijanovic N, DiPatrizio NV, et al. Plasma endocannabinoid levels in lean, overweight, and obese humans: relationships to intestinal permeability markers, inflammation, and incretin secretion. Am J Physiol‐Endocrinol Metabol. 2018;315(4):E489‐E495.</Citation></Reference><Reference><Citation>Brun P, Castagliuolo I, Leo VD, et al. Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. Am J Physiol‐Gastrointest liver Phys. 2007;292(2):G518‐G525.</Citation></Reference><Reference><Citation>Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Human gut microbes associated with obesity. Nature. 2006;444(7122):1022‐1023.</Citation></Reference><Reference><Citation>Turnbaugh PJ, Hamady M, Yatsunenko T, et al. A core gut microbiome in obese and lean twins. Nature. 2009;457(7228):480‐484.</Citation></Reference><Reference><Citation>Cox AJ, West NP, Cripps AW. Obesity, inflammation, and the gut microbiota. Lancet Diabetes Endocrinol. 2015;3(3):207‐215.</Citation></Reference><Reference><Citation>Welsh JA, Karpen S, Vos MB. Increasing prevalence of nonalcoholic fatty liver disease among United States adolescents, 1988–1994 to 2007–2010. J Pediatr. 2013;162(3):496‐500.e1.</Citation></Reference><Reference><Citation>Allen AM, Therneau TM, Larson JJ, Coward A, Somers VK, Kamath PS. Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: a 20 year‐community study. Hepatology. 2018;67(5):1726‐1736.</Citation></Reference><Reference><Citation>Miele L, Valenza V, La Torre G, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology. 2009;49(6):1877‐1887.</Citation></Reference><Reference><Citation>Fukui H. Role of gut dysbiosis in liver diseases: what have we learned so far? Diseases. 2019;7(4):58.</Citation></Reference><Reference><Citation>Chen Y, Yang F, Lu H, et al. Characterization of fecal microbial communities in patients with liver cirrhosis. Hepatology. 2011;54(2):562‐572.</Citation></Reference><Reference><Citation>Dogru M, Okada N, Asano‐Kato N, et al. Alterations of the ocular surface epithelial mucins 1, 2, 4 and the tear functions in patients with atopic keratoconjunctivitis. Clin Exp Allergy. 2006;36(12):1556‐1565.</Citation></Reference><Reference><Citation>Yeoh S, Church M, Lackie P, McGill J, Mota M, Hossain P. Increased conjunctival expression of protease activated receptor 2 (PAR‐2) in seasonal allergic conjunctivitis: a role for abnormal conjunctival epithelial permeability in disease pathogenesis? Br J Ophthalmol. 2011;95(9):1304‐1308.</Citation></Reference><Reference><Citation>Leonardi A, Daull P, Garrigue J‐S, et al. Conjunctival transcriptome analysis reveals the overexpression of multiple pattern recognition receptors in vernal keratoconjunctivitis. Ocul Surf. 2021;19:241‐248.</Citation></Reference><Reference><Citation>Leonardi A, Modugno R, Cavarzeran F, Rosani U. Metagenomic analysis of the conjunctival bacterial and fungal microbiome in vernal keratoconjunctivitis. Allergy. 2021;76(10):3215‐3217.</Citation></Reference><Reference><Citation>Rudnicka AR, Kapetanakis VV, Jarrar Z, et al. Incidence of late‐stage age‐related macular degeneration in American whites: systematic review and meta‐analysis. Am J Ophthalmol. 2015;160(1):85‐93.e3.</Citation></Reference><Reference><Citation>Kinnunen K, Petrovski G, Moe MC, Berta A, Kaarniranta K. Molecular mechanisms of retinal pigment epithelium damage and development of age‐related macular degeneration. Acta Ophthalmol. 2012;90(4):299‐309.</Citation></Reference><Reference><Citation>Zinkernagel MS, Zysset‐Burri DC, Keller I, et al. Association of the intestinal microbiome with the development of neovascular age‐related macular degeneration. Sci Rep. 2017;7(1):40826.</Citation></Reference><Reference><Citation>Wu Y, Wu J, Bu J, et al. High‐fat diet induces dry eye‐like ocular surface damages in murine. Ocul Surf. 2020;18(2):267‐276.</Citation></Reference><Reference><Citation>Kolko M, Horwitz A, Thygesen J, Jeppesen J, Torp‐Pedersen C. The prevalence and incidence of glaucoma in Denmark in a fifteen year period: a nationwide study. PLoS One. 2015;10(7):e0132048.</Citation></Reference><Reference><Citation>Usui T, Misawa Y, Honda N, Tomidokoro A, Yamagami S, Amano S. Nontraumatic keratomycosis caused by Alternaria in a glaucoma patient. Int Ophthalmol. 2009;29:529‐531.</Citation></Reference><Reference><Citation>Shin JH, Lee J‐W, Lim S‐H, Yoon BW, Lee Y, Seo JH. The microbiomes of the eyelid and buccal area of patients with uveitic glaucoma. BMC Ophthalmol. 2022;22(1):1‐11.</Citation></Reference><Reference><Citation>Chams H, Rostami M, Mohammadi S‐F, Ohno S. Epidemiology and prevalence of uveitis: review of literature. Iran J Ophthalmol. 2009;21(4):4‐16.</Citation></Reference><Reference><Citation>Gritz DC, Wong IG. Incidence and prevalence of uveitis in northern California: the northern California epidemiology of uveitis study. Ophthalmology. 2004;111(3):491‐500.</Citation></Reference><Reference><Citation>Zhang L, Borjini N, Lun Y, et al. CDCP1 regulates retinal pigmented epithelial barrier integrity for the development of experimental autoimmune uveitis. JCI Insight. 2022;7(18):e157038.</Citation></Reference><Reference><Citation>Jayasudha R, Chakravarthy SK, Prashanthi GS, Sharma S, Tyagi M, Shivaji S. Implicating dysbiosis of the gut fungal microbiome in uveitis, an inflammatory disease of the eye. Invest Ophthalmol Vis Sci. 2019;60(5):1384‐1393.</Citation></Reference><Reference><Citation>McCullough PA, Philbin EF, Spertus JA, Kaatz S, Sandberg KR, Weaver WD. Confirmation of a heart failure epidemic: findings from the resource utilization among congestive heart failure (REACH) study. J Am Coll Cardiol. 2002;39(1):60‐69.</Citation></Reference><Reference><Citation>Hoes A, Mosterd A, Grobbee D. An epidemic of heart failure? Recent evidence from Europe. Eur Heart J. 1998;19:L2‐L9.</Citation></Reference><Reference><Citation>Kannel WB, Ho K, Thom T. Changing epidemiological features of cardiac failure. Br Heart J. 1994;72(2 Suppl):S3.</Citation></Reference><Reference><Citation>Sandek A, Bauditz J, Swidsinski A, et al. Altered intestinal function in patients with chronic heart failure. J Am Coll Cardiol. 2007;50(16):1561‐1569.</Citation></Reference><Reference><Citation>Luedde M, Winkler T, Heinsen FA, et al. Heart failure is associated with depletion of core intestinal microbiota. ESC Heart Failure. 2017;4(3):282‐290.</Citation></Reference><Reference><Citation>Pasini E, Aquilani R, Testa C, et al. Pathogenic gut flora in patients with chronic heart failure. JACC: Heart Failure. 2016;4(3):220‐227.</Citation></Reference><Reference><Citation>Passarino G, Burlo P, Ciccone G, Comino A. Prevalence of myocarditis at autopsy in Turin, Italy. Arch Pathol Lab Med. 1997;121(6):619.</Citation></Reference><Reference><Citation>Kytö V, Saraste A, Voipio‐Pulkki L‐M, Saukko P. Incidence of fatal myocarditis: a population‐based study in Finland. Am J Epidemiol. 2007;165(5):570‐574.</Citation></Reference><Reference><Citation>Nieto Callejo M, Gallardo I, Gutierrez B, et al. Oleanolic acid protection against experimental autoimmune myocarditis modulates the microbiota and the intestinal barrier integrity. Eur Heart J. 2020;41(Supplement_2):ehaa946.3716.</Citation></Reference><Reference><Citation>Le CHH. The prevalence of anemia and moderate‐severe anemia in the US population (NHANES 2003–2012). PLoS One. 2016;11(11):e0166635.</Citation></Reference><Reference><Citation>MohanKumar K, Namachivayam K, Sivakumar N, et al. Severe neonatal anemia increases intestinal permeability by disrupting epithelial adherens junctions. Am J Physiol‐Gastrointestinal Liver Phys. 2020;318(4):G705‐G716.</Citation></Reference><Reference><Citation>Arthur CM, Nalbant D, Feldman HA, et al. Anemia induces gut inflammation and injury in an animal model of preterm infants. Transfusion. 2019;59(4):1233‐1245.</Citation></Reference><Reference><Citation>Long Y, Liang F, Guo R, et al. Gut microbiota signatures in gestational anemia. Front Cell Infect Microbiol. 2021;11:549678.</Citation></Reference><Reference><Citation>Muleviciene A, D'Amico F, Turroni S, Candela M, Jankauskiene A. Iron deficiency anemia‐related gut microbiota dysbiosis in infants and young children: a pilot study. Acta Microbiol Immunol Hung. 2018;65(4):551‐564.</Citation></Reference><Reference><Citation>Ren M, Ge Y, Qi J, et al. Dysbiosis of gut microbiota and its relationship with the regulatory T cells in patients with aplastic anemia. 2021.</Citation></Reference><Reference><Citation>Martin DL, MacDonald KL, White KE, Soler JT, Osterholm MT. The epidemiology and clinical aspects of the hemolytic uremic syndrome in Minnesota. N Engl J Med. 1990;323(17):1161‐1167.</Citation></Reference><Reference><Citation>Tarr PI, Neill MA, Allen J, Siccardi CJ, Watkins SL, Hickman RO. The increasing incidence of the hemolytic‐uremic syndrome in King County, Washington: lack of evidence for ascertainment bias. Am J Epidemiol. 1989;129(3):582‐586.</Citation></Reference><Reference><Citation>King AJ. Acute inflammation in the pathogenesis of hemolytic‐uremic syndrome. Kidney Int. 2002;61(4):1553‐1564.</Citation></Reference><Reference><Citation>Wan D, Liang X, Yang L, et al. Integration of gut microbiota and metabolomics for the hematopoiesis of Siwu paste on anemia rats. Heliyon. 2023;9:e18024.</Citation></Reference><Reference><Citation>Chawla LS, Fink M, Goldstein SL, et al. The epithelium as a target in sepsis. Shock. 2016;45(3):249‐258.</Citation></Reference><Reference><Citation>Liu Z, Li N, Fang H, et al. Enteric dysbiosis is associated with sepsis in patients. FASEB J. 2019;33(11):12299.</Citation></Reference><Reference><Citation>Tews HC, Kandulski A, Schmid S, et al. Contrast enhanced ultrasonography (CEUS) a novel tool to detect intestinal epithelial barrier dysfunction in severe COVID‐19 disease. Clin Hemorheol Microcirc. 2022;81(2):177‐190.</Citation></Reference><Reference><Citation>Sokolowska M, Lukasik ZM, Agache I, et al. Immunology of COVID‐19: mechanisms, clinical outcome, diagnostics, and perspectives—a report of the European academy of allergy and clinical immunology (EAACI). Allergy. 2020;75(10):2445‐2476.</Citation></Reference><Reference><Citation>Fiorito S, Soligo M, Gao Y, Ogulur I, Akdis CA, Bonini S. Is the epithelial barrier hypothesis the key to understanding the higher incidence and excess mortality during COVID‐19 pandemic? The case of Northern Italy. Allergy. 2022;77(5):1408‐1417.</Citation></Reference><Reference><Citation>Baeradeh N, Ghoddusi Johari M, Moftakhar L, Rezaeianzadeh R, Hosseini SV, Rezaianzadeh A. The prevalence and predictors of cardiovascular diseases in Kherameh cohort study: a population‐based study on 10,663 people in southern Iran. BMC Cardiovasc Disord. 2022;22(1):244.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>